KR102726269B1 - 범용 항-cd22 키메라 항원 수용체 조작된 면역 세포 - Google Patents

Info

Publication number

KR102726269B1

KR102726269B1 KR1020197032371A KR20197032371A KR102726269B1 KR 102726269 B1 KR102726269 B1 KR 102726269B1 KR 1020197032371 A KR1020197032371 A KR 1020197032371A KR 20197032371 A KR20197032371 A KR 20197032371A KR 102726269 B1 KR102726269 B1 KR 102726269B1

Authority

KR

South Korea

Prior art keywords

car

cell

cells

gene

cancer

Prior art date

2017-03-31

Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)

Active

Links

• Espacenet
• Global Dossier
• Discuss

• 108010019670 Chimeric Antigen Receptors Proteins 0.000 title claims abstract description 605
• 210000002865 immune cell Anatomy 0.000 title abstract description 131
• 206010028980 Neoplasm Diseases 0.000 claims abstract description 128
• 238000011282 treatment Methods 0.000 claims abstract description 80
• 101000884305 Homo sapiens B-cell receptor CD22 Proteins 0.000 claims abstract description 35
• 102100038080 B-cell receptor CD22 Human genes 0.000 claims abstract 23
• 101710153660 Nuclear receptor corepressor 2 Proteins 0.000 claims abstract 2
• 210000004027 cell Anatomy 0.000 claims description 463
• 108090000623 proteins and genes Proteins 0.000 claims description 252
• 210000001744 T-lymphocyte Anatomy 0.000 claims description 211
• 241000282414 Homo sapiens Species 0.000 claims description 94
• 201000011510 cancer Diseases 0.000 claims description 90
• 108090000765 processed proteins & peptides Proteins 0.000 claims description 85
• 230000027455 binding Effects 0.000 claims description 76
• 229960004641 rituximab Drugs 0.000 claims description 70
• 239000013598 vector Substances 0.000 claims description 69
• 102000004196 processed proteins & peptides Human genes 0.000 claims description 64
• 229920001184 polypeptide Polymers 0.000 claims description 63
• 208000024893 Acute lymphoblastic leukemia Diseases 0.000 claims description 61
• 239000003814 drug Substances 0.000 claims description 60
• 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 claims description 59
• 108010065524 CD52 Antigen Proteins 0.000 claims description 59
• 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 claims description 59
• 208000014697 Acute lymphocytic leukaemia Diseases 0.000 claims description 57
• 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 claims description 57
• 125000003275 alpha amino acid group Chemical group 0.000 claims description 54
• 239000008194 pharmaceutical composition Substances 0.000 claims description 51
• 230000011664 signaling Effects 0.000 claims description 51
• 102000040430 polynucleotide Human genes 0.000 claims description 49
• 108091033319 polynucleotide Proteins 0.000 claims description 49
• 239000002157 polynucleotide Substances 0.000 claims description 49
• 102100040678 Programmed cell death protein 1 Human genes 0.000 claims description 40
• 239000000427 antigen Substances 0.000 claims description 39
• 108091007433 antigens Proteins 0.000 claims description 39
• 102000036639 antigens Human genes 0.000 claims description 39
• 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 claims description 37
• 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 claims description 36
• 208000032852 chronic lymphocytic leukemia Diseases 0.000 claims description 35
• 230000001404 mediated effect Effects 0.000 claims description 34
• 101710089372 Programmed cell death protein 1 Proteins 0.000 claims description 27
• 208000032839 leukemia Diseases 0.000 claims description 25
• 206010025323 Lymphomas Diseases 0.000 claims description 23
• 238000004519 manufacturing process Methods 0.000 claims description 22
• 102000003984 Aryl Hydrocarbon Receptors Human genes 0.000 claims description 20
• 108090000448 Aryl Hydrocarbon Receptors Proteins 0.000 claims description 20
• 108010017550 Interleukin-10 Receptors Proteins 0.000 claims description 20
• 102000016715 Transforming Growth Factor beta Receptors Human genes 0.000 claims description 20
• 102000004551 Interleukin-10 Receptors Human genes 0.000 claims description 19
• 239000012634 fragment Substances 0.000 claims description 18
• 230000002489 hematologic effect Effects 0.000 claims description 16
• 101150096852 dck gene Proteins 0.000 claims description 14
• 101150043916 Cd52 gene Proteins 0.000 claims description 13
• 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims description 13
• 206010035226 Plasma cell myeloma Diseases 0.000 claims description 13
• 230000004068 intracellular signaling Effects 0.000 claims description 13
• 208000031261 Acute myeloid leukaemia Diseases 0.000 claims description 12
• 208000017604 Hodgkin disease Diseases 0.000 claims description 12
• 208000021519 Hodgkin lymphoma Diseases 0.000 claims description 12
• 208000010747 Hodgkins lymphoma Diseases 0.000 claims description 12
• 208000034578 Multiple myelomas Diseases 0.000 claims description 12
• 108091005735 TGF-beta receptors Proteins 0.000 claims description 12
• 238000009169 immunotherapy Methods 0.000 claims description 12
• 208000011691 Burkitt lymphomas Diseases 0.000 claims description 11
• 208000033776 Myeloid Acute Leukemia Diseases 0.000 claims description 11
• 230000001154 acute effect Effects 0.000 claims description 11
• 201000009277 hairy cell leukemia Diseases 0.000 claims description 11
• 239000000546 pharmaceutical excipient Substances 0.000 claims description 9
• 108010092867 Transforming Growth Factor beta Receptors Proteins 0.000 claims description 8
• 230000000527 lymphocytic effect Effects 0.000 claims description 8
• 101150076800 B2M gene Proteins 0.000 claims description 7
• 102000003814 Interleukin-10 Human genes 0.000 claims description 3
• 108090000174 Interleukin-10 Proteins 0.000 claims description 3
• 102100024217 CAMPATH-1 antigen Human genes 0.000 claims 1
• 238000012217 deletion Methods 0.000 abstract description 35
• 230000037430 deletion Effects 0.000 abstract description 35
• 230000009257 reactivity Effects 0.000 abstract description 2
• 102100029452 T cell receptor alpha chain constant Human genes 0.000 description 123
• 108091008874 T cell receptors Proteins 0.000 description 83
• 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 83
• 230000014509 gene expression Effects 0.000 description 68
• 238000000034 method Methods 0.000 description 62
• 208000025324 B-cell acute lymphoblastic leukemia Diseases 0.000 description 55
• 102000013135 CD52 Antigen Human genes 0.000 description 54
• 108010042407 Endonucleases Proteins 0.000 description 49
• 230000000694 effects Effects 0.000 description 46
• 229940079593 drug Drugs 0.000 description 45
• 108050005493 CD3 protein, epsilon/gamma/delta subunit Proteins 0.000 description 44
• 108010033174 Deoxycytidine kinase Proteins 0.000 description 44
• 102000017420 CD3 protein, epsilon/gamma/delta subunit Human genes 0.000 description 43
• 241000699670 Mus sp. Species 0.000 description 43
• 229960000548 alemtuzumab Drugs 0.000 description 43
• 102100029588 Deoxycytidine kinase Human genes 0.000 description 40
• 238000001727 in vivo Methods 0.000 description 39
• 150000007523 nucleic acids Chemical class 0.000 description 38
• 102100031780 Endonuclease Human genes 0.000 description 37
• 108010076504 Protein Sorting Signals Proteins 0.000 description 36
• 206010021143 Hypoxia Diseases 0.000 description 34
• 230000007954 hypoxia Effects 0.000 description 32
• 210000004986 primary T-cell Anatomy 0.000 description 31
• 235000001014 amino acid Nutrition 0.000 description 30
• 230000002779 inactivation Effects 0.000 description 30
• 108010081355 beta 2-Microglobulin Proteins 0.000 description 28
• 150000001413 amino acids Chemical class 0.000 description 27
• 230000008685 targeting Effects 0.000 description 27
• 229940024606 amino acid Drugs 0.000 description 26
• 101710163270 Nuclease Proteins 0.000 description 25
• 230000000735 allogeneic effect Effects 0.000 description 25
• 239000003446 ligand Substances 0.000 description 25
• 108020001756 ligand binding domains Proteins 0.000 description 25
• 235000018102 proteins Nutrition 0.000 description 25
• 102000004169 proteins and genes Human genes 0.000 description 25
• 150000003212 purines Chemical class 0.000 description 25
• 230000003834 intracellular effect Effects 0.000 description 24
• 108700018351 Major Histocompatibility Complex Proteins 0.000 description 23
• 230000019491 signal transduction Effects 0.000 description 23
• 230000020382 suppression by virus of host antigen processing and presentation of peptide antigen via MHC class I Effects 0.000 description 23
• 108060003951 Immunoglobulin Proteins 0.000 description 22
• 102000015736 beta 2-Microglobulin Human genes 0.000 description 22
• 102000018358 immunoglobulin Human genes 0.000 description 22
• 230000035772 mutation Effects 0.000 description 22
• 238000001890 transfection Methods 0.000 description 22
• 102000039446 nucleic acids Human genes 0.000 description 21
• 108020004707 nucleic acids Proteins 0.000 description 21
• 108091033409 CRISPR Proteins 0.000 description 20
• 230000002950 deficient Effects 0.000 description 20
• 108091026890 Coding region Proteins 0.000 description 19
• 101150094051 KO gene Proteins 0.000 description 19
• 102000053602 DNA Human genes 0.000 description 18
• 108020004414 DNA Proteins 0.000 description 18
• MJQUEDHRCUIRLF-TVIXENOKSA-N bryostatin 1 Chemical compound C([C@@H]1CC(/[C@@H]([C@@](C(C)(C)/C=C/2)(O)O1)OC(=O)/C=C/C=C/CCC)=C\C(=O)OC)[C@H]([C@@H](C)O)OC(=O)C[C@H](O)C[C@@H](O1)C[C@H](OC(C)=O)C(C)(C)[C@]1(O)C[C@@H]1C\C(=C\C(=O)OC)C[C@H]\2O1 MJQUEDHRCUIRLF-TVIXENOKSA-N 0.000 description 18
• 238000005520 cutting process Methods 0.000 description 18
• 238000012546 transfer Methods 0.000 description 18
• 238000003780 insertion Methods 0.000 description 17
• 230000037431 insertion Effects 0.000 description 17
• 238000002560 therapeutic procedure Methods 0.000 description 17
• -1 CD20 Proteins 0.000 description 16
• 108091028043 Nucleic acid sequence Proteins 0.000 description 16
• 230000004913 activation Effects 0.000 description 16
• 230000004083 survival effect Effects 0.000 description 16
• 238000010361 transduction Methods 0.000 description 16
• 230000026683 transduction Effects 0.000 description 16
• 239000002213 purine nucleotide Substances 0.000 description 15
• 210000004881 tumor cell Anatomy 0.000 description 15
• 208000009329 Graft vs Host Disease Diseases 0.000 description 14
• 102100031573 Hematopoietic progenitor cell antigen CD34 Human genes 0.000 description 14
• 101000777663 Homo sapiens Hematopoietic progenitor cell antigen CD34 Proteins 0.000 description 14
• 101000851376 Homo sapiens Tumor necrosis factor receptor superfamily member 8 Proteins 0.000 description 14
• 102100036857 Tumor necrosis factor receptor superfamily member 8 Human genes 0.000 description 14
• 208000024908 graft versus host disease Diseases 0.000 description 14
• 238000002347 injection Methods 0.000 description 14
• 239000007924 injection Substances 0.000 description 14
• 102000004533 Endonucleases Human genes 0.000 description 13
• 101000611936 Homo sapiens Programmed cell death protein 1 Proteins 0.000 description 13
• 239000000126 substance Substances 0.000 description 13
• DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 12
• 101100425901 Rattus norvegicus Tpm1 gene Proteins 0.000 description 12
• 230000000259 anti-tumor effect Effects 0.000 description 12
• 230000004540 complement-dependent cytotoxicity Effects 0.000 description 12
• 230000001472 cytotoxic effect Effects 0.000 description 12
• 238000000684 flow cytometry Methods 0.000 description 12
• 230000006870 function Effects 0.000 description 12
• 102000044389 human CD22 Human genes 0.000 description 12
• 230000001771 impaired effect Effects 0.000 description 12
• 238000000338 in vitro Methods 0.000 description 12
• 125000003729 nucleotide group Chemical group 0.000 description 12
• 102000004127 Cytokines Human genes 0.000 description 11
• 108090000695 Cytokines Proteins 0.000 description 11
• 102100032049 E3 ubiquitin-protein ligase LRSAM1 Human genes 0.000 description 11
• 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 description 11
• 108091054437 MHC class I family Proteins 0.000 description 11
• 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 description 11
• 210000003719 b-lymphocyte Anatomy 0.000 description 11
• 210000004369 blood Anatomy 0.000 description 11
• 239000008280 blood Substances 0.000 description 11
• 238000002512 chemotherapy Methods 0.000 description 11
• 230000004048 modification Effects 0.000 description 11
• 238000012986 modification Methods 0.000 description 11
• 239000002773 nucleotide Substances 0.000 description 11
• 102000005962 receptors Human genes 0.000 description 11
• 108020003175 receptors Proteins 0.000 description 11
• BGFTWECWAICPDG-UHFFFAOYSA-N 2-[bis(4-chlorophenyl)methyl]-4-n-[3-[bis(4-chlorophenyl)methyl]-4-(dimethylamino)phenyl]-1-n,1-n-dimethylbenzene-1,4-diamine Chemical compound C1=C(C(C=2C=CC(Cl)=CC=2)C=2C=CC(Cl)=CC=2)C(N(C)C)=CC=C1NC(C=1)=CC=C(N(C)C)C=1C(C=1C=CC(Cl)=CC=1)C1=CC=C(Cl)C=C1 BGFTWECWAICPDG-UHFFFAOYSA-N 0.000 description 10
• 108010008014 B-Cell Maturation Antigen Proteins 0.000 description 10
• 102000006942 B-Cell Maturation Antigen Human genes 0.000 description 10
• 241000699666 Mus <mouse, genus> Species 0.000 description 10
• 108010073062 Transcription Activator-Like Effectors Proteins 0.000 description 10
• 229960005539 bryostatin 1 Drugs 0.000 description 10
• 238000011161 development Methods 0.000 description 10
• 201000010099 disease Diseases 0.000 description 10
• 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 10
• 238000004520 electroporation Methods 0.000 description 10
• 229960000390 fludarabine Drugs 0.000 description 10
• GIUYCYHIANZCFB-FJFJXFQQSA-N fludarabine phosphate Chemical compound C1=NC=2C(N)=NC(F)=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@@H]1O GIUYCYHIANZCFB-FJFJXFQQSA-N 0.000 description 10
• 230000003211 malignant effect Effects 0.000 description 10
• 239000000203 mixture Substances 0.000 description 10
• 229920002477 rna polymer Polymers 0.000 description 10
• 210000001519 tissue Anatomy 0.000 description 10
• 102100034458 Hepatitis A virus cellular receptor 2 Human genes 0.000 description 9
• 101001057504 Homo sapiens Interferon-stimulated gene 20 kDa protein Proteins 0.000 description 9
• 101001055144 Homo sapiens Interleukin-2 receptor subunit alpha Proteins 0.000 description 9
• 238000004458 analytical method Methods 0.000 description 9
• 230000018109 developmental process Effects 0.000 description 9
• 239000012528 membrane Substances 0.000 description 9
• 229910052760 oxygen Inorganic materials 0.000 description 9
• 239000000047 product Substances 0.000 description 9
• 102100039498 Cytotoxic T-lymphocyte protein 4 Human genes 0.000 description 8
• 208000002250 Hematologic Neoplasms Diseases 0.000 description 8
• 102000008949 Histocompatibility Antigens Class I Human genes 0.000 description 8
• 102000017578 LAG3 Human genes 0.000 description 8
• 102100020718 Receptor-type tyrosine-protein kinase FLT3 Human genes 0.000 description 8
• 108700042076 T-Cell Receptor alpha Genes Proteins 0.000 description 8
• 125000000539 amino acid group Chemical group 0.000 description 8
• 238000003556 assay Methods 0.000 description 8
• 229960005520 bryostatin Drugs 0.000 description 8
• 201000005787 hematologic cancer Diseases 0.000 description 8
• 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 description 8
• 230000000670 limiting effect Effects 0.000 description 8
• 210000004698 lymphocyte Anatomy 0.000 description 8
• 230000004044 response Effects 0.000 description 8
• 230000003612 virological effect Effects 0.000 description 8
• FSPQCTGGIANIJZ-UHFFFAOYSA-N 2-[[(3,4-dimethoxyphenyl)-oxomethyl]amino]-4,5,6,7-tetrahydro-1-benzothiophene-3-carboxamide Chemical compound C1=C(OC)C(OC)=CC=C1C(=O)NC1=C(C(N)=O)C(CCCC2)=C2S1 FSPQCTGGIANIJZ-UHFFFAOYSA-N 0.000 description 7
• 206010005003 Bladder cancer Diseases 0.000 description 7
• 108091007741 Chimeric antigen receptor T cells Proteins 0.000 description 7
• 108020004705 Codon Proteins 0.000 description 7
• 102000004190 Enzymes Human genes 0.000 description 7
• 108090000790 Enzymes Proteins 0.000 description 7
• 241000282412 Homo Species 0.000 description 7
• 101000889276 Homo sapiens Cytotoxic T-lymphocyte protein 4 Proteins 0.000 description 7
• 102100037850 Interferon gamma Human genes 0.000 description 7
• 108010074328 Interferon-gamma Proteins 0.000 description 7
• 208000010505 Nose Neoplasms Diseases 0.000 description 7
• 108010047620 Phytohemagglutinins Proteins 0.000 description 7
• 101710151245 Receptor-type tyrosine-protein kinase FLT3 Proteins 0.000 description 7
• 108060008683 Tumor Necrosis Factor Receptor Proteins 0.000 description 7
• 230000010056 antibody-dependent cellular cytotoxicity Effects 0.000 description 7
• 239000011324 bead Substances 0.000 description 7
• 210000001185 bone marrow Anatomy 0.000 description 7
• MUIWQCKLQMOUAT-AKUNNTHJSA-N bryostatin 20 Natural products COC(=O)C=C1C[C@@]2(C)C[C@]3(O)O[C@](C)(C[C@@H](O)CC(=O)O[C@](C)(C[C@@]4(C)O[C@](O)(CC5=CC(=O)O[C@]45C)C(C)(C)C=C[C@@](C)(C1)O2)[C@@H](C)O)C[C@H](OC(=O)C(C)(C)C)C3(C)C MUIWQCKLQMOUAT-AKUNNTHJSA-N 0.000 description 7
• 229940112129 campath Drugs 0.000 description 7
• 239000003795 chemical substances by application Substances 0.000 description 7
• 238000003776 cleavage reaction Methods 0.000 description 7
• 238000003501 co-culture Methods 0.000 description 7
• 206010052015 cytokine release syndrome Diseases 0.000 description 7
• 230000001086 cytosolic effect Effects 0.000 description 7
• 229940088598 enzyme Drugs 0.000 description 7
• 239000013604 expression vector Substances 0.000 description 7
• 230000001939 inductive effect Effects 0.000 description 7
• 210000004379 membrane Anatomy 0.000 description 7
• 230000001885 phytohemagglutinin Effects 0.000 description 7
• 239000013612 plasmid Substances 0.000 description 7
• 230000007017 scission Effects 0.000 description 7
• 210000000130 stem cell Anatomy 0.000 description 7
• 238000002054 transplantation Methods 0.000 description 7
• 102000003298 tumor necrosis factor receptor Human genes 0.000 description 7
• 101150013553 CD40 gene Proteins 0.000 description 6
• 238000010354 CRISPR gene editing Methods 0.000 description 6
• 102100032742 Histone-lysine N-methyltransferase SETD2 Human genes 0.000 description 6
• 101000654725 Homo sapiens Histone-lysine N-methyltransferase SETD2 Proteins 0.000 description 6
• 102100027268 Interferon-stimulated gene 20 kDa protein Human genes 0.000 description 6
• 108010002350 Interleukin-2 Proteins 0.000 description 6
• 102000000588 Interleukin-2 Human genes 0.000 description 6
• 208000008839 Kidney Neoplasms Diseases 0.000 description 6
• 206010023825 Laryngeal cancer Diseases 0.000 description 6
• 206010058467 Lung neoplasm malignant Diseases 0.000 description 6
• 108010064548 Lymphocyte Function-Associated Antigen-1 Proteins 0.000 description 6
• 241001465754 Metazoa Species 0.000 description 6
• 241001529936 Murinae Species 0.000 description 6
• 206010038389 Renal cancer Diseases 0.000 description 6
• 208000024770 Thyroid neoplasm Diseases 0.000 description 6
• 102100040245 Tumor necrosis factor receptor superfamily member 5 Human genes 0.000 description 6
• 238000013459 approach Methods 0.000 description 6
• QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 6
• 230000000295 complement effect Effects 0.000 description 6
• 230000003750 conditioning effect Effects 0.000 description 6
• 230000001461 cytolytic effect Effects 0.000 description 6
• 238000002784 cytotoxicity assay Methods 0.000 description 6
• 238000010362 genome editing Methods 0.000 description 6
• 239000003018 immunosuppressive agent Substances 0.000 description 6
• 201000010982 kidney cancer Diseases 0.000 description 6
• 206010023841 laryngeal neoplasm Diseases 0.000 description 6
• 201000007270 liver cancer Diseases 0.000 description 6
• 208000014018 liver neoplasm Diseases 0.000 description 6
• 201000005202 lung cancer Diseases 0.000 description 6
• 208000020816 lung neoplasm Diseases 0.000 description 6
• 239000002609 medium Substances 0.000 description 6
• 239000001301 oxygen Substances 0.000 description 6
• 210000004990 primary immune cell Anatomy 0.000 description 6
• 230000003248 secreting effect Effects 0.000 description 6
• 241000894007 species Species 0.000 description 6
• 238000006467 substitution reaction Methods 0.000 description 6
• 230000001225 therapeutic effect Effects 0.000 description 6
• 201000002510 thyroid cancer Diseases 0.000 description 6
• 230000035899 viability Effects 0.000 description 6
• MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 5
• FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 5
• 102100029822 B- and T-lymphocyte attenuator Human genes 0.000 description 5
• 238000011740 C57BL/6 mouse Methods 0.000 description 5
• 102100038078 CD276 antigen Human genes 0.000 description 5
• 101710185679 CD276 antigen Proteins 0.000 description 5
• 102100035793 CD83 antigen Human genes 0.000 description 5
• 102100028712 Cytosolic purine 5'-nucleotidase Human genes 0.000 description 5
• 241000702421 Dependoparvovirus Species 0.000 description 5
• 208000022072 Gallbladder Neoplasms Diseases 0.000 description 5
• 239000004471 Glycine Substances 0.000 description 5
• 101000864344 Homo sapiens B- and T-lymphocyte attenuator Proteins 0.000 description 5
• 101100166600 Homo sapiens CD28 gene Proteins 0.000 description 5
• 101000946856 Homo sapiens CD83 antigen Proteins 0.000 description 5
• 101000917383 Homo sapiens Deoxycytidine kinase Proteins 0.000 description 5
• 101001023379 Homo sapiens Lysosome-associated membrane glycoprotein 1 Proteins 0.000 description 5
• 102100035133 Lysosome-associated membrane glycoprotein 1 Human genes 0.000 description 5
• 241000700605 Viruses Species 0.000 description 5
• 230000008901 benefit Effects 0.000 description 5
• 230000001684 chronic effect Effects 0.000 description 5
• 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 5
• 230000003013 cytotoxicity Effects 0.000 description 5
• 231100000135 cytotoxicity Toxicity 0.000 description 5
• 230000006378 damage Effects 0.000 description 5
• 230000001747 exhibiting effect Effects 0.000 description 5
• 201000010175 gallbladder cancer Diseases 0.000 description 5
• 238000003209 gene knockout Methods 0.000 description 5
• 208000014829 head and neck neoplasm Diseases 0.000 description 5
• 210000000987 immune system Anatomy 0.000 description 5
• 230000001976 improved effect Effects 0.000 description 5
• 238000001802 infusion Methods 0.000 description 5
• 230000036210 malignancy Effects 0.000 description 5
• 230000007246 mechanism Effects 0.000 description 5
• 238000010172 mouse model Methods 0.000 description 5
• 230000007170 pathology Effects 0.000 description 5
• 238000003752 polymerase chain reaction Methods 0.000 description 5
• 230000035755 proliferation Effects 0.000 description 5
• 230000002829 reductive effect Effects 0.000 description 5
• 102220080600 rs797046116 Human genes 0.000 description 5
• 210000000952 spleen Anatomy 0.000 description 5
• 150000003431 steroids Chemical class 0.000 description 5
• 235000000346 sugar Nutrition 0.000 description 5
• 239000013603 viral vector Substances 0.000 description 5
• 206010061424 Anal cancer Diseases 0.000 description 4
• 102000006306 Antigen Receptors Human genes 0.000 description 4
• 108010083359 Antigen Receptors Proteins 0.000 description 4
• 208000007860 Anus Neoplasms Diseases 0.000 description 4
• BPYKTIZUTYGOLE-IFADSCNNSA-N Bilirubin Chemical compound N1C(=O)C(C)=C(C=C)\C1=C\C1=C(C)C(CCC(O)=O)=C(CC2=C(C(C)=C(\C=C/3C(=C(C=C)C(=O)N\3)C)N2)CCC(O)=O)N1 BPYKTIZUTYGOLE-IFADSCNNSA-N 0.000 description 4
• 208000016778 CD4+/CD56+ hematodermic neoplasm Diseases 0.000 description 4
• 108010047041 Complementarity Determining Regions Proteins 0.000 description 4
• CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 4
• 206010059866 Drug resistance Diseases 0.000 description 4
• 108010087819 Fc receptors Proteins 0.000 description 4
• 102000009109 Fc receptors Human genes 0.000 description 4
• 201000003741 Gastrointestinal carcinoma Diseases 0.000 description 4
• 102000003676 Glucocorticoid Receptors Human genes 0.000 description 4
• 108090000079 Glucocorticoid Receptors Proteins 0.000 description 4
• 206010066476 Haematological malignancy Diseases 0.000 description 4
• 108010007707 Hepatitis A Virus Cellular Receptor 2 Proteins 0.000 description 4
• 101710083479 Hepatitis A virus cellular receptor 2 homolog Proteins 0.000 description 4
• 101001137987 Homo sapiens Lymphocyte activation gene 3 protein Proteins 0.000 description 4
• 101000582254 Homo sapiens Nuclear receptor corepressor 2 Proteins 0.000 description 4
• 101000934341 Homo sapiens T-cell surface glycoprotein CD5 Proteins 0.000 description 4
• 101150030213 Lag3 gene Proteins 0.000 description 4
• 208000008771 Lymphadenopathy Diseases 0.000 description 4
• 206010061309 Neoplasm progression Diseases 0.000 description 4
• 108010038807 Oligopeptides Proteins 0.000 description 4
• 102000015636 Oligopeptides Human genes 0.000 description 4
• 206010033128 Ovarian cancer Diseases 0.000 description 4
• 206010061535 Ovarian neoplasm Diseases 0.000 description 4
• 206010061902 Pancreatic neoplasm Diseases 0.000 description 4
• 206010060862 Prostate cancer Diseases 0.000 description 4
• 108010041388 Ribonucleotide Reductases Proteins 0.000 description 4
• 102000000505 Ribonucleotide Reductases Human genes 0.000 description 4
• 230000006044 T cell activation Effects 0.000 description 4
• 229940126547 T-cell immunoglobulin mucin-3 Drugs 0.000 description 4
• 102100025244 T-cell surface glycoprotein CD5 Human genes 0.000 description 4
• 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 4
• 238000010171 animal model Methods 0.000 description 4
• 201000011165 anus cancer Diseases 0.000 description 4
• 230000001580 bacterial effect Effects 0.000 description 4
• 230000003197 catalytic effect Effects 0.000 description 4
• 238000004113 cell culture Methods 0.000 description 4
• 230000010261 cell growth Effects 0.000 description 4
• 210000003169 central nervous system Anatomy 0.000 description 4
• DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 4
• 229960004397 cyclophosphamide Drugs 0.000 description 4
• 210000005220 cytoplasmic tail Anatomy 0.000 description 4
• OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical compound NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 description 4
• 231100000263 cytotoxicity test Toxicity 0.000 description 4
• 238000013461 design Methods 0.000 description 4
• 230000005782 double-strand break Effects 0.000 description 4
• 239000012636 effector Substances 0.000 description 4
• 238000005516 engineering process Methods 0.000 description 4
• 238000002474 experimental method Methods 0.000 description 4
• 108020001507 fusion proteins Proteins 0.000 description 4
• 102000037865 fusion proteins Human genes 0.000 description 4
• 238000012239 gene modification Methods 0.000 description 4
• 230000002068 genetic effect Effects 0.000 description 4
• 230000005017 genetic modification Effects 0.000 description 4
• 235000013617 genetically modified food Nutrition 0.000 description 4
• 230000012010 growth Effects 0.000 description 4
• 230000000415 inactivating effect Effects 0.000 description 4
• 229960003130 interferon gamma Drugs 0.000 description 4
• 238000001990 intravenous administration Methods 0.000 description 4
• 239000007788 liquid Substances 0.000 description 4
• 208000018555 lymphatic system disease Diseases 0.000 description 4
• 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 4
• 239000000463 material Substances 0.000 description 4
• 231100000682 maximum tolerated dose Toxicity 0.000 description 4
• 108020004999 messenger RNA Proteins 0.000 description 4
• 208000037830 nasal cancer Diseases 0.000 description 4
• 201000002528 pancreatic cancer Diseases 0.000 description 4
• 208000008443 pancreatic carcinoma Diseases 0.000 description 4
• 239000013610 patient sample Substances 0.000 description 4
• 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 4
• 201000002628 peritoneum cancer Diseases 0.000 description 4
• 230000002688 persistence Effects 0.000 description 4
• 230000000638 stimulation Effects 0.000 description 4
• 238000012360 testing method Methods 0.000 description 4
• WYWHKKSPHMUBEB-UHFFFAOYSA-N tioguanine Chemical compound N1C(N)=NC(=S)C2=C1N=CN2 WYWHKKSPHMUBEB-UHFFFAOYSA-N 0.000 description 4
• 230000005751 tumor progression Effects 0.000 description 4
• 241001430294 unidentified retrovirus Species 0.000 description 4
• 201000005112 urinary bladder cancer Diseases 0.000 description 4
• 206010005949 Bone cancer Diseases 0.000 description 3
• 208000018084 Bone neoplasm Diseases 0.000 description 3
• 208000003174 Brain Neoplasms Diseases 0.000 description 3
• 206010006187 Breast cancer Diseases 0.000 description 3
• 208000026310 Breast neoplasm Diseases 0.000 description 3
• 102100027207 CD27 antigen Human genes 0.000 description 3
• 210000001266 CD8-positive T-lymphocyte Anatomy 0.000 description 3
• 102000016289 Cell Adhesion Molecules Human genes 0.000 description 3
• 108010067225 Cell Adhesion Molecules Proteins 0.000 description 3
• 206010008342 Cervix carcinoma Diseases 0.000 description 3
• 206010009944 Colon cancer Diseases 0.000 description 3
• PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 3
• 108010036949 Cyclosporine Proteins 0.000 description 3
• UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytarabine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 description 3
• 206010050685 Cytokine storm Diseases 0.000 description 3
• 102100025137 Early activation antigen CD69 Human genes 0.000 description 3
• 208000000461 Esophageal Neoplasms Diseases 0.000 description 3
• 201000008808 Fibrosarcoma Diseases 0.000 description 3
• 101000980814 Homo sapiens CAMPATH-1 antigen Proteins 0.000 description 3
• 101000914511 Homo sapiens CD27 antigen Proteins 0.000 description 3
• 101000934374 Homo sapiens Early activation antigen CD69 Proteins 0.000 description 3
• 101001083151 Homo sapiens Interleukin-10 receptor subunit alpha Proteins 0.000 description 3
• 101001003149 Homo sapiens Interleukin-10 receptor subunit beta Proteins 0.000 description 3
• 101001138062 Homo sapiens Leukocyte-associated immunoglobulin-like receptor 1 Proteins 0.000 description 3
• 101000878605 Homo sapiens Low affinity immunoglobulin epsilon Fc receptor Proteins 0.000 description 3
• 101001109503 Homo sapiens NKG2-C type II integral membrane protein Proteins 0.000 description 3
• 101000601724 Homo sapiens Paired box protein Pax-5 Proteins 0.000 description 3
• 101000831007 Homo sapiens T-cell immunoreceptor with Ig and ITIM domains Proteins 0.000 description 3
• 101000610604 Homo sapiens Tumor necrosis factor receptor superfamily member 10B Proteins 0.000 description 3
• 102000037982 Immune checkpoint proteins Human genes 0.000 description 3
• 108091008036 Immune checkpoint proteins Proteins 0.000 description 3
• 108010021625 Immunoglobulin Fragments Proteins 0.000 description 3
• 102000008394 Immunoglobulin Fragments Human genes 0.000 description 3
• 102100030236 Interleukin-10 receptor subunit alpha Human genes 0.000 description 3
• 102100020788 Interleukin-10 receptor subunit beta Human genes 0.000 description 3
• CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 3
• ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 3
• OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 3
• KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 3
• 241000713666 Lentivirus Species 0.000 description 3
• 102100020943 Leukocyte-associated immunoglobulin-like receptor 1 Human genes 0.000 description 3
• 102100038007 Low affinity immunoglobulin epsilon Fc receptor Human genes 0.000 description 3
• 102000043129 MHC class I family Human genes 0.000 description 3
• 208000000172 Medulloblastoma Diseases 0.000 description 3
• 208000003445 Mouth Neoplasms Diseases 0.000 description 3
• 102100022683 NKG2-C type II integral membrane protein Human genes 0.000 description 3
• 208000001894 Nasopharyngeal Neoplasms Diseases 0.000 description 3
• 206010061306 Nasopharyngeal cancer Diseases 0.000 description 3
• 108090000028 Neprilysin Proteins 0.000 description 3
• 102000003729 Neprilysin Human genes 0.000 description 3
• 206010030155 Oesophageal carcinoma Diseases 0.000 description 3
• 108091034117 Oligonucleotide Proteins 0.000 description 3
• 102100037504 Paired box protein Pax-5 Human genes 0.000 description 3
• 208000000236 Prostatic Neoplasms Diseases 0.000 description 3
• 208000015634 Rectal Neoplasms Diseases 0.000 description 3
• MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 3
• 102000001613 Sialic Acid Binding Ig-like Lectin 2 Human genes 0.000 description 3
• 108010029157 Sialic Acid Binding Ig-like Lectin 2 Proteins 0.000 description 3
• 208000000453 Skin Neoplasms Diseases 0.000 description 3
• 208000032383 Soft tissue cancer Diseases 0.000 description 3
• 208000000102 Squamous Cell Carcinoma of Head and Neck Diseases 0.000 description 3
• 208000005718 Stomach Neoplasms Diseases 0.000 description 3
• 230000006052 T cell proliferation Effects 0.000 description 3
• 102100024834 T-cell immunoreceptor with Ig and ITIM domains Human genes 0.000 description 3
• 238000010459 TALEN Methods 0.000 description 3
• 108091007178 TNFRSF10A Proteins 0.000 description 3
• QJJXYPPXXYFBGM-LFZNUXCKSA-N Tacrolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1\C=C(/C)[C@@H]1[C@H](C)[C@@H](O)CC(=O)[C@H](CC=C)/C=C(C)/C[C@H](C)C[C@H](OC)[C@H]([C@H](C[C@H]2C)OC)O[C@@]2(O)C(=O)C(=O)N2CCCC[C@H]2C(=O)O1 QJJXYPPXXYFBGM-LFZNUXCKSA-N 0.000 description 3
• 208000024313 Testicular Neoplasms Diseases 0.000 description 3
• 206010057644 Testis cancer Diseases 0.000 description 3
• 108091028113 Trans-activating crRNA Proteins 0.000 description 3
• 108010043645 Transcription Activator-Like Effector Nucleases Proteins 0.000 description 3
• 102100040113 Tumor necrosis factor receptor superfamily member 10A Human genes 0.000 description 3
• 102100022153 Tumor necrosis factor receptor superfamily member 4 Human genes 0.000 description 3
• 101710165473 Tumor necrosis factor receptor superfamily member 4 Proteins 0.000 description 3
• 208000023915 Ureteral Neoplasms Diseases 0.000 description 3
• 206010046392 Ureteric cancer Diseases 0.000 description 3
• 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 3
• KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 3
• 206010047741 Vulval cancer Diseases 0.000 description 3
• 208000004354 Vulvar Neoplasms Diseases 0.000 description 3
• 230000009471 action Effects 0.000 description 3
• 230000003213 activating effect Effects 0.000 description 3
• 101150087698 alpha gene Proteins 0.000 description 3
• 206010065867 alveolar rhabdomyosarcoma Diseases 0.000 description 3
• 230000029918 bioluminescence Effects 0.000 description 3
• 238000005415 bioluminescence Methods 0.000 description 3
• 201000001531 bladder carcinoma Diseases 0.000 description 3
• 230000037396 body weight Effects 0.000 description 3
• 201000006491 bone marrow cancer Diseases 0.000 description 3
• 238000010322 bone marrow transplantation Methods 0.000 description 3
• GXJABQQUPOEUTA-RDJZCZTQSA-N bortezomib Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)B(O)O)NC(=O)C=1N=CC=NC=1)C1=CC=CC=C1 GXJABQQUPOEUTA-RDJZCZTQSA-N 0.000 description 3
• 229960001467 bortezomib Drugs 0.000 description 3
• 238000002659 cell therapy Methods 0.000 description 3
• 201000010881 cervical cancer Diseases 0.000 description 3
• 208000006990 cholangiocarcinoma Diseases 0.000 description 3
• 229960001265 ciclosporin Drugs 0.000 description 3
• WDDPHFBMKLOVOX-AYQXTPAHSA-N clofarabine Chemical compound C1=NC=2C(N)=NC(Cl)=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1F WDDPHFBMKLOVOX-AYQXTPAHSA-N 0.000 description 3
• 229960000928 clofarabine Drugs 0.000 description 3
• 208000029742 colonic neoplasm Diseases 0.000 description 3
• 150000001875 compounds Chemical class 0.000 description 3
• 229930182912 cyclosporin Natural products 0.000 description 3
• 230000009089 cytolysis Effects 0.000 description 3
• 210000004443 dendritic cell Anatomy 0.000 description 3
• 230000001419 dependent effect Effects 0.000 description 3
• 238000001514 detection method Methods 0.000 description 3
• UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 3
• 208000018554 digestive system carcinoma Diseases 0.000 description 3
• 230000008030 elimination Effects 0.000 description 3
• 238000003379 elimination reaction Methods 0.000 description 3
• 201000004101 esophageal cancer Diseases 0.000 description 3
• 238000011156 evaluation Methods 0.000 description 3
• 208000024519 eye neoplasm Diseases 0.000 description 3
• 206010017758 gastric cancer Diseases 0.000 description 3
• 125000000404 glutamine group Chemical group N[C@@H](CCC(N)=O)C(=O)* 0.000 description 3
• 201000010536 head and neck cancer Diseases 0.000 description 3
• 201000000459 head and neck squamous cell carcinoma Diseases 0.000 description 3
• 102000043738 human CD52 Human genes 0.000 description 3
• 210000005260 human cell Anatomy 0.000 description 3
• 230000036737 immune function Effects 0.000 description 3
• 230000028993 immune response Effects 0.000 description 3
• 229940124589 immunosuppressive drug Drugs 0.000 description 3
• 208000015181 infectious disease Diseases 0.000 description 3
• 208000027866 inflammatory disease Diseases 0.000 description 3
• 230000031146 intracellular signal transduction Effects 0.000 description 3
• 208000012987 lip and oral cavity carcinoma Diseases 0.000 description 3
• 210000001165 lymph node Anatomy 0.000 description 3
• 208000006178 malignant mesothelioma Diseases 0.000 description 3
• 239000003550 marker Substances 0.000 description 3
• 201000001441 melanoma Diseases 0.000 description 3
• 229960005027 natalizumab Drugs 0.000 description 3
• 210000000822 natural killer cell Anatomy 0.000 description 3
• 239000013642 negative control Substances 0.000 description 3
• 238000007481 next generation sequencing Methods 0.000 description 3
• 208000002154 non-small cell lung carcinoma Diseases 0.000 description 3
• 201000008106 ocular cancer Diseases 0.000 description 3
• 210000000056 organ Anatomy 0.000 description 3
• 230000001575 pathological effect Effects 0.000 description 3
• 239000013600 plasmid vector Substances 0.000 description 3
• 230000003389 potentiating effect Effects 0.000 description 3
• 239000002243 precursor Substances 0.000 description 3
• 238000001959 radiotherapy Methods 0.000 description 3
• 238000011084 recovery Methods 0.000 description 3
• 206010038038 rectal cancer Diseases 0.000 description 3
• 201000001275 rectum cancer Diseases 0.000 description 3
• 230000009467 reduction Effects 0.000 description 3
• 230000001105 regulatory effect Effects 0.000 description 3
• 239000000523 sample Substances 0.000 description 3
• 230000028327 secretion Effects 0.000 description 3
• 210000002966 serum Anatomy 0.000 description 3
• 201000000849 skin cancer Diseases 0.000 description 3
• 210000004989 spleen cell Anatomy 0.000 description 3
• 238000011272 standard treatment Methods 0.000 description 3
• 201000011549 stomach cancer Diseases 0.000 description 3
• QJJXYPPXXYFBGM-SHYZHZOCSA-N tacrolimus Natural products CO[C@H]1C[C@H](CC[C@@H]1O)C=C(C)[C@H]2OC(=O)[C@H]3CCCCN3C(=O)C(=O)[C@@]4(O)O[C@@H]([C@H](C[C@H]4C)OC)[C@@H](C[C@H](C)CC(=C[C@@H](CC=C)C(=O)C[C@H](O)[C@H]2C)C)OC QJJXYPPXXYFBGM-SHYZHZOCSA-N 0.000 description 3
• 201000003120 testicular cancer Diseases 0.000 description 3
• 238000011426 transformation method Methods 0.000 description 3
• 230000001052 transient effect Effects 0.000 description 3
• 230000010474 transient expression Effects 0.000 description 3
• OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 3
• 241000701161 unidentified adenovirus Species 0.000 description 3
• 208000010570 urinary bladder carcinoma Diseases 0.000 description 3
• 239000004474 valine Substances 0.000 description 3
• 201000005102 vulva cancer Diseases 0.000 description 3
• CDKIEBFIMCSCBB-UHFFFAOYSA-N 1-(6,7-dimethoxy-3,4-dihydro-1h-isoquinolin-2-yl)-3-(1-methyl-2-phenylpyrrolo[2,3-b]pyridin-3-yl)prop-2-en-1-one;hydrochloride Chemical compound Cl.C1C=2C=C(OC)C(OC)=CC=2CCN1C(=O)C=CC(C1=CC=CN=C1N1C)=C1C1=CC=CC=C1 CDKIEBFIMCSCBB-UHFFFAOYSA-N 0.000 description 2
• 101710175516 14 kDa zinc-binding protein Proteins 0.000 description 2
• YKBGVTZYEHREMT-KVQBGUIXSA-N 2'-deoxyguanosine Chemical compound C1=NC=2C(=O)NC(N)=NC=2N1[C@H]1C[C@H](O)[C@@H](CO)O1 YKBGVTZYEHREMT-KVQBGUIXSA-N 0.000 description 2
• 108010082808 4-1BB Ligand Proteins 0.000 description 2
• MJZJYWCQPMNPRM-UHFFFAOYSA-N 6,6-dimethyl-1-[3-(2,4,5-trichlorophenoxy)propoxy]-1,6-dihydro-1,3,5-triazine-2,4-diamine Chemical compound CC1(C)N=C(N)N=C(N)N1OCCCOC1=CC(Cl)=C(Cl)C=C1Cl MJZJYWCQPMNPRM-UHFFFAOYSA-N 0.000 description 2
• 239000013607 AAV vector Substances 0.000 description 2
• 108010074708 B7-H1 Antigen Proteins 0.000 description 2
• 102100022970 Basic leucine zipper transcriptional factor ATF-like Human genes 0.000 description 2
• 102100025221 CD70 antigen Human genes 0.000 description 2
• 108090000397 Caspase 3 Proteins 0.000 description 2
• 102100029855 Caspase-3 Human genes 0.000 description 2
• 102100038918 Caspase-6 Human genes 0.000 description 2
• 102100038902 Caspase-7 Human genes 0.000 description 2
• 102100026548 Caspase-8 Human genes 0.000 description 2
• PHEDXBVPIONUQT-UHFFFAOYSA-N Cocarcinogen A1 Natural products CCCCCCCCCCCCCC(=O)OC1C(C)C2(O)C3C=C(C)C(=O)C3(O)CC(CO)=CC2C2C1(OC(C)=O)C2(C)C PHEDXBVPIONUQT-UHFFFAOYSA-N 0.000 description 2
• 206010010144 Completed suicide Diseases 0.000 description 2
• 102100027816 Cytotoxic and regulatory T-cell molecule Human genes 0.000 description 2
• 230000006820 DNA synthesis Effects 0.000 description 2
• AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 2
• 101000889900 Enterobacteria phage T4 Intron-associated endonuclease 1 Proteins 0.000 description 2
• 102100026693 FAS-associated death domain protein Human genes 0.000 description 2
• 108090000331 Firefly luciferases Proteins 0.000 description 2
• 102100027581 Forkhead box protein P3 Human genes 0.000 description 2
• 102100040754 Guanylate cyclase soluble subunit alpha-1 Human genes 0.000 description 2
• 102100040735 Guanylate cyclase soluble subunit alpha-2 Human genes 0.000 description 2
• 102100040739 Guanylate cyclase soluble subunit beta-1 Human genes 0.000 description 2
• 102100028963 Guanylate cyclase soluble subunit beta-2 Human genes 0.000 description 2
• 208000031886 HIV Infections Diseases 0.000 description 2
• 208000037357 HIV infectious disease Diseases 0.000 description 2
• 102100028967 HLA class I histocompatibility antigen, alpha chain G Human genes 0.000 description 2
• 108010024164 HLA-G Antigens Proteins 0.000 description 2
• 208000005176 Hepatitis C Diseases 0.000 description 2
• 102100035081 Homeobox protein TGIF1 Human genes 0.000 description 2
• 101000903742 Homo sapiens Basic leucine zipper transcriptional factor ATF-like Proteins 0.000 description 2
• 101000934356 Homo sapiens CD70 antigen Proteins 0.000 description 2
• 101000741087 Homo sapiens Caspase-6 Proteins 0.000 description 2
• 101000741014 Homo sapiens Caspase-7 Proteins 0.000 description 2
• 101000983528 Homo sapiens Caspase-8 Proteins 0.000 description 2
• 101000911074 Homo sapiens FAS-associated death domain protein Proteins 0.000 description 2
• 101000861452 Homo sapiens Forkhead box protein P3 Proteins 0.000 description 2
• 101001038755 Homo sapiens Guanylate cyclase soluble subunit alpha-1 Proteins 0.000 description 2
• 101001038749 Homo sapiens Guanylate cyclase soluble subunit alpha-2 Proteins 0.000 description 2
• 101001038731 Homo sapiens Guanylate cyclase soluble subunit beta-1 Proteins 0.000 description 2
• 101001059095 Homo sapiens Guanylate cyclase soluble subunit beta-2 Proteins 0.000 description 2
• 101000596925 Homo sapiens Homeobox protein TGIF1 Proteins 0.000 description 2
• 101001046870 Homo sapiens Hypoxia-inducible factor 1-alpha Proteins 0.000 description 2
• 101000599048 Homo sapiens Interleukin-6 receptor subunit alpha Proteins 0.000 description 2
• 101000599056 Homo sapiens Interleukin-6 receptor subunit beta Proteins 0.000 description 2
• 101000984189 Homo sapiens Leukocyte immunoglobulin-like receptor subfamily B member 2 Proteins 0.000 description 2
• 101000984186 Homo sapiens Leukocyte immunoglobulin-like receptor subfamily B member 4 Proteins 0.000 description 2
• 101100495232 Homo sapiens MS4A1 gene Proteins 0.000 description 2
• 101000581981 Homo sapiens Neural cell adhesion molecule 1 Proteins 0.000 description 2
• 101000692259 Homo sapiens Phosphoprotein associated with glycosphingolipid-enriched microdomains 1 Proteins 0.000 description 2
• 101001068027 Homo sapiens Serine/threonine-protein phosphatase 2A catalytic subunit alpha isoform Proteins 0.000 description 2
• 101001068019 Homo sapiens Serine/threonine-protein phosphatase 2A catalytic subunit beta isoform Proteins 0.000 description 2
• 101000863883 Homo sapiens Sialic acid-binding Ig-like lectin 9 Proteins 0.000 description 2
• 101000688930 Homo sapiens Signaling threshold-regulating transmembrane adapter 1 Proteins 0.000 description 2
• 101000740162 Homo sapiens Sodium- and chloride-dependent transporter XTRP3 Proteins 0.000 description 2
• 101000596234 Homo sapiens T-cell surface protein tactile Proteins 0.000 description 2
• 101100207070 Homo sapiens TNFSF8 gene Proteins 0.000 description 2
• 101000597785 Homo sapiens Tumor necrosis factor receptor superfamily member 6B Proteins 0.000 description 2
• 101001135589 Homo sapiens Tyrosine-protein phosphatase non-receptor type 22 Proteins 0.000 description 2
• 101000617285 Homo sapiens Tyrosine-protein phosphatase non-receptor type 6 Proteins 0.000 description 2
• 108010091358 Hypoxanthine Phosphoribosyltransferase Proteins 0.000 description 2
• 102100029098 Hypoxanthine-guanine phosphoribosyltransferase Human genes 0.000 description 2
• 102100022875 Hypoxia-inducible factor 1-alpha Human genes 0.000 description 2
• 206010061218 Inflammation Diseases 0.000 description 2
• 108050003558 Interleukin-17 Proteins 0.000 description 2
• 102000013691 Interleukin-17 Human genes 0.000 description 2
• 102100030703 Interleukin-22 Human genes 0.000 description 2
• 108090001005 Interleukin-6 Proteins 0.000 description 2
• 102000004889 Interleukin-6 Human genes 0.000 description 2
• 102100037792 Interleukin-6 receptor subunit alpha Human genes 0.000 description 2
• 102100037795 Interleukin-6 receptor subunit beta Human genes 0.000 description 2
• 108020003285 Isocitrate lyase Proteins 0.000 description 2
• HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 2
• AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 2
• FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 2
• COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 2
• AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 2
• QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 2
• ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 2
• 102100025583 Leukocyte immunoglobulin-like receptor subfamily B member 2 Human genes 0.000 description 2
• 102100025578 Leukocyte immunoglobulin-like receptor subfamily B member 4 Human genes 0.000 description 2
• 108060001084 Luciferase Proteins 0.000 description 2
• 239000005089 Luciferase Substances 0.000 description 2
• 102100030301 MHC class I polypeptide-related sequence A Human genes 0.000 description 2
• 241000124008 Mammalia Species 0.000 description 2
• 108010061593 Member 14 Tumor Necrosis Factor Receptors Proteins 0.000 description 2
• 102100025748 Mothers against decapentaplegic homolog 3 Human genes 0.000 description 2
• 101710143111 Mothers against decapentaplegic homolog 3 Proteins 0.000 description 2
• 102100025725 Mothers against decapentaplegic homolog 4 Human genes 0.000 description 2
• 101710143112 Mothers against decapentaplegic homolog 4 Proteins 0.000 description 2
• 101100508818 Mus musculus Inpp5k gene Proteins 0.000 description 2
• 101100407308 Mus musculus Pdcd1lg2 gene Proteins 0.000 description 2
• 101100207071 Mus musculus Tnfsf8 gene Proteins 0.000 description 2
• 102000004473 OX40 Ligand Human genes 0.000 description 2
• 108010042215 OX40 Ligand Proteins 0.000 description 2
• 241000283973 Oryctolagus cuniculus Species 0.000 description 2
• 102100024894 PR domain zinc finger protein 1 Human genes 0.000 description 2
• 102100026066 Phosphoprotein associated with glycosphingolipid-enriched microdomains 1 Human genes 0.000 description 2
• 241000709664 Picornaviridae Species 0.000 description 2
• 108010009975 Positive Regulatory Domain I-Binding Factor 1 Proteins 0.000 description 2
• 108700030875 Programmed Cell Death 1 Ligand 2 Proteins 0.000 description 2
• 102100024216 Programmed cell death 1 ligand 1 Human genes 0.000 description 2
• 102100024213 Programmed cell death 1 ligand 2 Human genes 0.000 description 2
• 229940124158 Protease/peptidase inhibitor Drugs 0.000 description 2
• 229940123924 Protein kinase C inhibitor Drugs 0.000 description 2
• 239000012980 RPMI-1640 medium Substances 0.000 description 2
• 101100366438 Rattus norvegicus Sphkap gene Proteins 0.000 description 2
• 108010029477 STAT5 Transcription Factor Proteins 0.000 description 2
• 102100034464 Serine/threonine-protein phosphatase 2A catalytic subunit alpha isoform Human genes 0.000 description 2
• 102100034470 Serine/threonine-protein phosphatase 2A catalytic subunit beta isoform Human genes 0.000 description 2
• 102100029946 Sialic acid-binding Ig-like lectin 7 Human genes 0.000 description 2
• 102100024481 Signal transducer and activator of transcription 5A Human genes 0.000 description 2
• 102100024453 Signaling threshold-regulating transmembrane adapter 1 Human genes 0.000 description 2
• 101000987219 Sus scrofa Pregnancy-associated glycoprotein 1 Proteins 0.000 description 2
• 230000005867 T cell response Effects 0.000 description 2
• 208000031673 T-Cell Cutaneous Lymphoma Diseases 0.000 description 2
• 102100035268 T-cell surface protein tactile Human genes 0.000 description 2
• AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 2
• 239000004473 Threonine Substances 0.000 description 2
• QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 2
• 108060008682 Tumor Necrosis Factor Proteins 0.000 description 2
• 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 2
• 102100032100 Tumor necrosis factor ligand superfamily member 8 Human genes 0.000 description 2
• 102100032101 Tumor necrosis factor ligand superfamily member 9 Human genes 0.000 description 2
• 102100040112 Tumor necrosis factor receptor superfamily member 10B Human genes 0.000 description 2
• 102100028785 Tumor necrosis factor receptor superfamily member 14 Human genes 0.000 description 2
• 102100035284 Tumor necrosis factor receptor superfamily member 6B Human genes 0.000 description 2
• 102100033138 Tyrosine-protein phosphatase non-receptor type 22 Human genes 0.000 description 2
• 102100021657 Tyrosine-protein phosphatase non-receptor type 6 Human genes 0.000 description 2
• 208000036142 Viral infection Diseases 0.000 description 2
• JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 2
• 229960000446 abciximab Drugs 0.000 description 2
• 238000010317 ablation therapy Methods 0.000 description 2
• 239000012190 activator Substances 0.000 description 2
• 229960002964 adalimumab Drugs 0.000 description 2
• 238000007792 addition Methods 0.000 description 2
• 239000000654 additive Substances 0.000 description 2
• OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 description 2
• 208000014619 adult acute lymphoblastic leukemia Diseases 0.000 description 2
• 201000011184 adult acute lymphocytic leukemia Diseases 0.000 description 2
• 239000000556 agonist Substances 0.000 description 2
• 230000004075 alteration Effects 0.000 description 2
• 210000002255 anal canal Anatomy 0.000 description 2
• 238000009175 antibody therapy Methods 0.000 description 2
• 210000000612 antigen-presenting cell Anatomy 0.000 description 2
• 239000002246 antineoplastic agent Substances 0.000 description 2
• 125000000637 arginyl group Chemical group N[C@@H](CCCNC(N)=N)C(=O)* 0.000 description 2
• 229960004669 basiliximab Drugs 0.000 description 2
• 229960003270 belimumab Drugs 0.000 description 2
• 102000012740 beta Adrenergic Receptors Human genes 0.000 description 2
• 108010079452 beta Adrenergic Receptors Proteins 0.000 description 2
• 229960000397 bevacizumab Drugs 0.000 description 2
• 230000008275 binding mechanism Effects 0.000 description 2
• 229960000455 brentuximab vedotin Drugs 0.000 description 2
• 229960001838 canakinumab Drugs 0.000 description 2
• 229910052799 carbon Inorganic materials 0.000 description 2
• 239000000969 carrier Substances 0.000 description 2
• 230000006037 cell lysis Effects 0.000 description 2
• 230000004663 cell proliferation Effects 0.000 description 2
• 239000002458 cell surface marker Substances 0.000 description 2
• 208000015114 central nervous system disease Diseases 0.000 description 2
• 201000010039 central nervous system leukemia Diseases 0.000 description 2
• 229960003115 certolizumab pegol Drugs 0.000 description 2
• 229960005395 cetuximab Drugs 0.000 description 2
• 229940044683 chemotherapy drug Drugs 0.000 description 2
• 230000002759 chromosomal effect Effects 0.000 description 2
• 210000000349 chromosome Anatomy 0.000 description 2
• 108010072917 class-I restricted T cell-associated molecule Proteins 0.000 description 2
• 238000010276 construction Methods 0.000 description 2
• 229940109239 creatinine Drugs 0.000 description 2
• 238000012258 culturing Methods 0.000 description 2
• 201000007241 cutaneous T cell lymphoma Diseases 0.000 description 2
• 229960000684 cytarabine Drugs 0.000 description 2
• 238000003568 cytokine secretion assay Methods 0.000 description 2
• 229940104302 cytosine Drugs 0.000 description 2
• 229960002806 daclizumab Drugs 0.000 description 2
• 238000002716 delivery method Methods 0.000 description 2
• 229960001251 denosumab Drugs 0.000 description 2
• 229960003957 dexamethasone Drugs 0.000 description 2
• 230000004069 differentiation Effects 0.000 description 2
• 230000003828 downregulation Effects 0.000 description 2
• 230000009977 dual effect Effects 0.000 description 2
• 229960002224 eculizumab Drugs 0.000 description 2
• 229960000284 efalizumab Drugs 0.000 description 2
• 108010050663 endodeoxyribonuclease CreI Proteins 0.000 description 2
• 230000007717 exclusion Effects 0.000 description 2
• 210000004700 fetal blood Anatomy 0.000 description 2
• OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical class C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 2
• 230000004927 fusion Effects 0.000 description 2
• 229960000578 gemtuzumab Drugs 0.000 description 2
• 238000001415 gene therapy Methods 0.000 description 2
• 229960001743 golimumab Drugs 0.000 description 2
• UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical compound O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 description 2
• 210000002443 helper t lymphocyte Anatomy 0.000 description 2
• 208000002672 hepatitis B Diseases 0.000 description 2
• 210000003630 histaminocyte Anatomy 0.000 description 2
• HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 2
• 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 description 2
• 230000036039 immunity Effects 0.000 description 2
• 229940027941 immunoglobulin g Drugs 0.000 description 2
• 230000001506 immunosuppresive effect Effects 0.000 description 2
• 229940125721 immunosuppressive agent Drugs 0.000 description 2
• 230000005917 in vivo anti-tumor Effects 0.000 description 2
• 238000011503 in vivo imaging Methods 0.000 description 2
• 238000011534 incubation Methods 0.000 description 2
• 230000002757 inflammatory effect Effects 0.000 description 2
• 230000004054 inflammatory process Effects 0.000 description 2
• 229960000598 infliximab Drugs 0.000 description 2
• 206010022000 influenza Diseases 0.000 description 2
• 239000003112 inhibitor Substances 0.000 description 2
• NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
• 230000010354 integration Effects 0.000 description 2
• 201000007450 intrahepatic cholangiocarcinoma Diseases 0.000 description 2
• 230000002601 intratumoral effect Effects 0.000 description 2
• 229960005386 ipilimumab Drugs 0.000 description 2
• AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 2
• 229960000310 isoleucine Drugs 0.000 description 2
• 230000002147 killing effect Effects 0.000 description 2
• 230000007774 longterm Effects 0.000 description 2
• 238000011469 lymphodepleting chemotherapy Methods 0.000 description 2
• 208000026037 malignant tumor of neck Diseases 0.000 description 2
• 210000004962 mammalian cell Anatomy 0.000 description 2
• 201000006512 mast cell neoplasm Diseases 0.000 description 2
• 210000003519 mature b lymphocyte Anatomy 0.000 description 2
• 238000005259 measurement Methods 0.000 description 2
• 229960000485 methotrexate Drugs 0.000 description 2
• 239000010445 mica Substances 0.000 description 2
• 229910052618 mica group Inorganic materials 0.000 description 2
• HPNSFSBZBAHARI-UHFFFAOYSA-N micophenolic acid Natural products OC1=C(CC=C(C)CCC(O)=O)C(OC)=C(C)C2=C1C(=O)OC2 HPNSFSBZBAHARI-UHFFFAOYSA-N 0.000 description 2
• 201000003956 middle ear cancer Diseases 0.000 description 2
• 238000010369 molecular cloning Methods 0.000 description 2
• 238000009126 molecular therapy Methods 0.000 description 2
• 239000000178 monomer Substances 0.000 description 2
• 229960003816 muromonab-cd3 Drugs 0.000 description 2
• HPNSFSBZBAHARI-RUDMXATFSA-N mycophenolic acid Chemical compound OC1=C(C\C=C(/C)CCC(O)=O)C(OC)=C(C)C2=C1C(=O)OC2 HPNSFSBZBAHARI-RUDMXATFSA-N 0.000 description 2
• 201000005962 mycosis fungoides Diseases 0.000 description 2
• 230000032965 negative regulation of cell volume Effects 0.000 description 2
• 230000006780 non-homologous end joining Effects 0.000 description 2
• 229960002450 ofatumumab Drugs 0.000 description 2
• 229960000470 omalizumab Drugs 0.000 description 2
• 238000004806 packaging method and process Methods 0.000 description 2
• 229960000402 palivizumab Drugs 0.000 description 2
• 229960001972 panitumumab Drugs 0.000 description 2
• 230000037361 pathway Effects 0.000 description 2
• 230000035515 penetration Effects 0.000 description 2
• 239000000137 peptide hydrolase inhibitor Substances 0.000 description 2
• 210000005259 peripheral blood Anatomy 0.000 description 2
• 239000011886 peripheral blood Substances 0.000 description 2
• COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 2
• PHEDXBVPIONUQT-RGYGYFBISA-N phorbol 13-acetate 12-myristate Chemical compound C([C@]1(O)C(=O)C(C)=C[C@H]1[C@@]1(O)[C@H](C)[C@H]2OC(=O)CCCCCCCCCCCCC)C(CO)=C[C@H]1[C@H]1[C@]2(OC(C)=O)C1(C)C PHEDXBVPIONUQT-RGYGYFBISA-N 0.000 description 2
• 208000025638 primary cutaneous T-cell non-Hodgkin lymphoma Diseases 0.000 description 2
• 108020001580 protein domains Proteins 0.000 description 2
• 239000003881 protein kinase C inhibitor Substances 0.000 description 2
• 238000000746 purification Methods 0.000 description 2
• 150000003230 pyrimidines Chemical class 0.000 description 2
• 229960003876 ranibizumab Drugs 0.000 description 2
• ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 description 2
• 230000007420 reactivation Effects 0.000 description 2
• 238000003259 recombinant expression Methods 0.000 description 2
• 210000003289 regulatory T cell Anatomy 0.000 description 2
• 238000009877 rendering Methods 0.000 description 2
• 230000010076 replication Effects 0.000 description 2
• 108091008146 restriction endonucleases Proteins 0.000 description 2
• 238000010839 reverse transcription Methods 0.000 description 2
• 238000012216 screening Methods 0.000 description 2
• 230000035945 sensitivity Effects 0.000 description 2
• 125000003607 serino group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C(O[H])([H])[H] 0.000 description 2
• 229960002930 sirolimus Drugs 0.000 description 2
• QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 description 2
• 201000002314 small intestine cancer Diseases 0.000 description 2
• DAEPDZWVDSPTHF-UHFFFAOYSA-M sodium pyruvate Chemical compound [Na+].CC(=O)C([O-])=O DAEPDZWVDSPTHF-UHFFFAOYSA-M 0.000 description 2
• 125000006850 spacer group Chemical group 0.000 description 2
• 230000010473 stable expression Effects 0.000 description 2
• 238000010186 staining Methods 0.000 description 2
• UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
• 230000009885 systemic effect Effects 0.000 description 2
• 210000001550 testis Anatomy 0.000 description 2
• RWQNBRDOKXIBIV-UHFFFAOYSA-N thymine Chemical compound CC1=CNC(=O)NC1=O RWQNBRDOKXIBIV-UHFFFAOYSA-N 0.000 description 2
• 229960003087 tioguanine Drugs 0.000 description 2
• 229960003989 tocilizumab Drugs 0.000 description 2
• 229960005267 tositumomab Drugs 0.000 description 2
• 230000032258 transport Effects 0.000 description 2
• 229960000575 trastuzumab Drugs 0.000 description 2
• 235000011178 triphosphate Nutrition 0.000 description 2
• 239000001226 triphosphate Substances 0.000 description 2
• 125000002264 triphosphate group Chemical group [H]OP(=O)(O[H])OP(=O)(O[H])OP(=O)(O[H])O* 0.000 description 2
• UNXRWKVEANCORM-UHFFFAOYSA-N triphosphoric acid Chemical compound OP(O)(=O)OP(O)(=O)OP(O)(O)=O UNXRWKVEANCORM-UHFFFAOYSA-N 0.000 description 2
• 238000013414 tumor xenograft model Methods 0.000 description 2
• 230000003827 upregulation Effects 0.000 description 2
• 229960003824 ustekinumab Drugs 0.000 description 2
• 229960004914 vedolizumab Drugs 0.000 description 2
• 239000003981 vehicle Substances 0.000 description 2
• 210000003462 vein Anatomy 0.000 description 2
• 230000002861 ventricular Effects 0.000 description 2
• 108700026220 vif Genes Proteins 0.000 description 2
• HKZAAJSTFUZYTO-LURJTMIESA-N (2s)-2-[[2-[[2-[[2-[(2-aminoacetyl)amino]acetyl]amino]acetyl]amino]acetyl]amino]-3-hydroxypropanoic acid Chemical compound NCC(=O)NCC(=O)NCC(=O)NCC(=O)N[C@@H](CO)C(O)=O HKZAAJSTFUZYTO-LURJTMIESA-N 0.000 description 1
• MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 1
• DSSYKIVIOFKYAU-XCBNKYQSSA-N (R)-camphor Chemical compound C1C[C@@]2(C)C(=O)C[C@@H]1C2(C)C DSSYKIVIOFKYAU-XCBNKYQSSA-N 0.000 description 1
• CKTSBUTUHBMZGZ-SHYZEUOFSA-N 2'‐deoxycytidine Chemical compound O=C1N=C(N)C=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 CKTSBUTUHBMZGZ-SHYZEUOFSA-N 0.000 description 1
• HIYAVKIYRIFSCZ-CYEMHPAKSA-N 5-(methylamino)-2-[[(2S,3R,5R,6S,8R,9R)-3,5,9-trimethyl-2-[(2S)-1-oxo-1-(1H-pyrrol-2-yl)propan-2-yl]-1,7-dioxaspiro[5.5]undecan-8-yl]methyl]-1,3-benzoxazole-4-carboxylic acid Chemical compound O=C([C@@H](C)[C@H]1O[C@@]2([C@@H](C[C@H]1C)C)O[C@@H]([C@@H](CC2)C)CC=1OC2=CC=C(C(=C2N=1)C(O)=O)NC)C1=CC=CN1 HIYAVKIYRIFSCZ-CYEMHPAKSA-N 0.000 description 1
• 108010013238 70-kDa Ribosomal Protein S6 Kinases Proteins 0.000 description 1
• KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical group N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 1
• 229930024421 Adenine Natural products 0.000 description 1
• GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 1
• 241000972680 Adeno-associated virus - 6 Species 0.000 description 1
• 241000710929 Alphavirus Species 0.000 description 1
• 241000212977 Andira Species 0.000 description 1
• 241000710189 Aphthovirus Species 0.000 description 1
• 239000004475 Arginine Substances 0.000 description 1
• 239000000592 Artificial Cell Substances 0.000 description 1
• 108010031480 Artificial Receptors Proteins 0.000 description 1
• 206010003445 Ascites Diseases 0.000 description 1
• DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
• 208000023275 Autoimmune disease Diseases 0.000 description 1
• 241000271566 Aves Species 0.000 description 1
• 208000004736 B-Cell Leukemia Diseases 0.000 description 1
• 208000003950 B-cell lymphoma Diseases 0.000 description 1
• 208000028564 B-cell non-Hodgkin lymphoma Diseases 0.000 description 1
• 241000894006 Bacteria Species 0.000 description 1
• 208000035143 Bacterial infection Diseases 0.000 description 1
• 241000283690 Bos taurus Species 0.000 description 1
• 241000700675 Bugula neritina Species 0.000 description 1
• 208000023611 Burkitt leukaemia Diseases 0.000 description 1
• 238000011357 CAR T-cell therapy Methods 0.000 description 1
• 229940124296 CD52 monoclonal antibody Drugs 0.000 description 1
• 210000001239 CD8-positive, alpha-beta cytotoxic T lymphocyte Anatomy 0.000 description 1
• 108010021064 CTLA-4 Antigen Proteins 0.000 description 1
• 229940045513 CTLA4 antagonist Drugs 0.000 description 1
• 101100510617 Caenorhabditis elegans sel-8 gene Proteins 0.000 description 1
• 102000004631 Calcineurin Human genes 0.000 description 1
• 108010042955 Calcineurin Proteins 0.000 description 1
• OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
• 102100025466 Carcinoembryonic antigen-related cell adhesion molecule 3 Human genes 0.000 description 1
• 208000005623 Carcinogenesis Diseases 0.000 description 1
• 201000009030 Carcinoma Diseases 0.000 description 1
• 102100026549 Caspase-10 Human genes 0.000 description 1
• 206010057248 Cell death Diseases 0.000 description 1
• VWFCHDSQECPREK-LURJTMIESA-N Cidofovir Chemical compound NC=1C=CN(C[C@@H](CO)OCP(O)(O)=O)C(=O)N=1 VWFCHDSQECPREK-LURJTMIESA-N 0.000 description 1
• 241000723346 Cinnamomum camphora Species 0.000 description 1
• 241000711573 Coronaviridae Species 0.000 description 1
• 101710095468 Cyclase Proteins 0.000 description 1
• 241000701022 Cytomegalovirus Species 0.000 description 1
• 210000004128 D cell Anatomy 0.000 description 1
• 230000007018 DNA scission Effects 0.000 description 1
• 241000450599 DNA viruses Species 0.000 description 1
• 230000004568 DNA-binding Effects 0.000 description 1
• CKTSBUTUHBMZGZ-UHFFFAOYSA-N Deoxycytidine Natural products O=C1N=C(N)C=CN1C1OC(CO)C(O)C1 CKTSBUTUHBMZGZ-UHFFFAOYSA-N 0.000 description 1
• 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
• 238000002965 ELISA Methods 0.000 description 1
• 108091029865 Exogenous DNA Proteins 0.000 description 1
• 108060002716 Exonuclease Proteins 0.000 description 1
• 229920001917 Ficoll Polymers 0.000 description 1
• 241000710831 Flavivirus Species 0.000 description 1
• 102000052907 GIY-YIG endonucleases Human genes 0.000 description 1
• 108700035841 GIY-YIG endonucleases Proteins 0.000 description 1
• 240000005702 Galium aparine Species 0.000 description 1
• 235000014820 Galium aparine Nutrition 0.000 description 1
• WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
• 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 1
• 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 1
• 241000941423 Grom virus Species 0.000 description 1
• 108020005004 Guide RNA Proteins 0.000 description 1
• 102100030595 HLA class II histocompatibility antigen gamma chain Human genes 0.000 description 1
• 108050008753 HNH endonucleases Proteins 0.000 description 1
• 102000000310 HNH endonucleases Human genes 0.000 description 1
• 102100028008 Heme oxygenase 2 Human genes 0.000 description 1
• 206010073069 Hepatic cancer Diseases 0.000 description 1
• 241000238631 Hexapoda Species 0.000 description 1
• 102100022132 High affinity immunoglobulin epsilon receptor subunit gamma Human genes 0.000 description 1
• 108091010847 High affinity immunoglobulin epsilon receptor subunit gamma Proteins 0.000 description 1
• 101000937544 Homo sapiens Beta-2-microglobulin Proteins 0.000 description 1
• 101100220044 Homo sapiens CD34 gene Proteins 0.000 description 1
• 101000914337 Homo sapiens Carcinoembryonic antigen-related cell adhesion molecule 3 Proteins 0.000 description 1
• 101000983518 Homo sapiens Caspase-10 Proteins 0.000 description 1
• 101000912053 Homo sapiens Cytidine deaminase Proteins 0.000 description 1
• 101001082627 Homo sapiens HLA class II histocompatibility antigen gamma chain Proteins 0.000 description 1
• 101001079615 Homo sapiens Heme oxygenase 2 Proteins 0.000 description 1
• 101001068133 Homo sapiens Hepatitis A virus cellular receptor 2 Proteins 0.000 description 1
• 101001002657 Homo sapiens Interleukin-2 Proteins 0.000 description 1
• 101001091194 Homo sapiens Peptidyl-prolyl cis-trans isomerase G Proteins 0.000 description 1
• 101000932478 Homo sapiens Receptor-type tyrosine-protein kinase FLT3 Proteins 0.000 description 1
• 101000738771 Homo sapiens Receptor-type tyrosine-protein phosphatase C Proteins 0.000 description 1
• 101000863882 Homo sapiens Sialic acid-binding Ig-like lectin 7 Proteins 0.000 description 1
• 101000634853 Homo sapiens T cell receptor alpha chain constant Proteins 0.000 description 1
• 101000946860 Homo sapiens T-cell surface glycoprotein CD3 epsilon chain Proteins 0.000 description 1
• 101000926525 Homo sapiens eIF-2-alpha kinase GCN2 Proteins 0.000 description 1
• 241000701044 Human gammaherpesvirus 4 Species 0.000 description 1
• 206010020751 Hypersensitivity Diseases 0.000 description 1
• 206010021042 Hypopharyngeal cancer Diseases 0.000 description 1
• 206010056305 Hypopharyngeal neoplasm Diseases 0.000 description 1
• 101150106931 IFNG gene Proteins 0.000 description 1
• 102000018071 Immunoglobulin Fc Fragments Human genes 0.000 description 1
• 108010091135 Immunoglobulin Fc Fragments Proteins 0.000 description 1
• 108090001061 Insulin Proteins 0.000 description 1
• 102100023915 Insulin Human genes 0.000 description 1
• 102100034343 Integrase Human genes 0.000 description 1
• 108010061833 Integrases Proteins 0.000 description 1
• 102000003816 Interleukin-13 Human genes 0.000 description 1
• 108090000176 Interleukin-13 Proteins 0.000 description 1
• 102100033454 Interleukin-17F Human genes 0.000 description 1
• 108010038453 Interleukin-2 Receptors Proteins 0.000 description 1
• 102000010789 Interleukin-2 Receptors Human genes 0.000 description 1
• 102100026878 Interleukin-2 receptor subunit alpha Human genes 0.000 description 1
• 102000004388 Interleukin-4 Human genes 0.000 description 1
• 108090000978 Interleukin-4 Proteins 0.000 description 1
• 108010002616 Interleukin-5 Proteins 0.000 description 1
• 102100039897 Interleukin-5 Human genes 0.000 description 1
• 108010002335 Interleukin-9 Proteins 0.000 description 1
• 102000000585 Interleukin-9 Human genes 0.000 description 1
• 108020004684 Internal Ribosome Entry Sites Proteins 0.000 description 1
• 108700021430 Kruppel-Like Factor 4 Proteins 0.000 description 1
• XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
• ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 1
• QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
• ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
• DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 1
• WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
• ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
• KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
• FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
• 101150043187 LAX2 gene Proteins 0.000 description 1
• 102000004856 Lectins Human genes 0.000 description 1
• 108090001090 Lectins Proteins 0.000 description 1
• 206010024291 Leukaemias acute myeloid Diseases 0.000 description 1
• 208000028018 Lymphocytic leukaemia Diseases 0.000 description 1
• KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
• 239000004472 Lysine Substances 0.000 description 1
• 206010025537 Malignant anorectal neoplasms Diseases 0.000 description 1
• 201000005505 Measles Diseases 0.000 description 1
• 102000012750 Membrane Glycoproteins Human genes 0.000 description 1
• 108010090054 Membrane Glycoproteins Proteins 0.000 description 1
• 102000018697 Membrane Proteins Human genes 0.000 description 1
• 108010052285 Membrane Proteins Proteins 0.000 description 1
• 206010027458 Metastases to lung Diseases 0.000 description 1
• 229930191564 Monensin Natural products 0.000 description 1
• GAOZTHIDHYLHMS-UHFFFAOYSA-N Monensin A Natural products O1C(CC)(C2C(CC(O2)C2C(CC(C)C(O)(CO)O2)C)C)CCC1C(O1)(C)CCC21CC(O)C(C)C(C(C)C(OC)C(C)C(O)=O)O2 GAOZTHIDHYLHMS-UHFFFAOYSA-N 0.000 description 1
• 102100025751 Mothers against decapentaplegic homolog 2 Human genes 0.000 description 1
• 101710143123 Mothers against decapentaplegic homolog 2 Proteins 0.000 description 1
• 101000687343 Mus musculus PR domain zinc finger protein 1 Proteins 0.000 description 1
• 101100351020 Mus musculus Pax5 gene Proteins 0.000 description 1
• 101100268066 Mus musculus Zap70 gene Proteins 0.000 description 1
• 102100038895 Myc proto-oncogene protein Human genes 0.000 description 1
• 101710135898 Myc proto-oncogene protein Proteins 0.000 description 1
• OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 1
• 102100027347 Neural cell adhesion molecule 1 Human genes 0.000 description 1
• 102100029438 Nitric oxide synthase, inducible Human genes 0.000 description 1
• 101710089543 Nitric oxide synthase, inducible Proteins 0.000 description 1
• 241000714209 Norwalk virus Species 0.000 description 1
• 108091007494 Nucleic acid- binding domains Proteins 0.000 description 1
• 108700026244 Open Reading Frames Proteins 0.000 description 1
• 101710126211 POU domain, class 5, transcription factor 1 Proteins 0.000 description 1
• 208000030852 Parasitic disease Diseases 0.000 description 1
• 229930182555 Penicillin Natural products 0.000 description 1
• JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
• 208000009565 Pharyngeal Neoplasms Diseases 0.000 description 1
• 206010034811 Pharyngeal cancer Diseases 0.000 description 1
• 208000002151 Pleural effusion Diseases 0.000 description 1
• 208000008691 Precursor B-Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 description 1
• ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
• 102000001253 Protein Kinase Human genes 0.000 description 1
• 108090000315 Protein Kinase C Proteins 0.000 description 1
• 102000003923 Protein Kinase C Human genes 0.000 description 1
• 102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 1
• 108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 1
• 241000125945 Protoparvovirus Species 0.000 description 1
• 201000004681 Psoriasis Diseases 0.000 description 1
• CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 1
• 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 1
• 206010037742 Rabies Diseases 0.000 description 1
• 241000711798 Rabies lyssavirus Species 0.000 description 1
• 101100247004 Rattus norvegicus Qsox1 gene Proteins 0.000 description 1
• 102100037422 Receptor-type tyrosine-protein phosphatase C Human genes 0.000 description 1
• 108020004511 Recombinant DNA Proteins 0.000 description 1
• 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
• 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
• 241000702263 Reovirus sp. Species 0.000 description 1
• 108091081062 Repeated sequence (DNA) Proteins 0.000 description 1
• 208000016624 Retinal neoplasm Diseases 0.000 description 1
• 241000712907 Retroviridae Species 0.000 description 1
• 101150086694 SLC22A3 gene Proteins 0.000 description 1
• 206010039491 Sarcoma Diseases 0.000 description 1
• 108091081021 Sense strand Proteins 0.000 description 1
• 206010070834 Sensitisation Diseases 0.000 description 1
• 238000012300 Sequence Analysis Methods 0.000 description 1
• 241000287219 Serinus canaria Species 0.000 description 1
• 102100029965 Sialic acid-binding Ig-like lectin 9 Human genes 0.000 description 1
• 241000700584 Simplexvirus Species 0.000 description 1
• 241000713675 Spumavirus Species 0.000 description 1
• 230000010782 T cell mediated cytotoxicity Effects 0.000 description 1
• 108010092262 T-Cell Antigen Receptors Proteins 0.000 description 1
• 206010042971 T-cell lymphoma Diseases 0.000 description 1
• 208000027585 T-cell non-Hodgkin lymphoma Diseases 0.000 description 1
• 102100035794 T-cell surface glycoprotein CD3 epsilon chain Human genes 0.000 description 1
• 101710150448 Transcriptional regulator Myc Proteins 0.000 description 1
• 102000004887 Transforming Growth Factor beta Human genes 0.000 description 1
• 108090001012 Transforming Growth Factor beta Proteins 0.000 description 1
• 108700019146 Transgenes Proteins 0.000 description 1
• 206010052779 Transplant rejections Diseases 0.000 description 1
• 208000006593 Urologic Neoplasms Diseases 0.000 description 1
• 206010046865 Vaccinia virus infection Diseases 0.000 description 1
• 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 1
• 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 1
• 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
• 241000711975 Vesicular stomatitis virus Species 0.000 description 1
• 108020005202 Viral DNA Proteins 0.000 description 1
• 108020000999 Viral RNA Proteins 0.000 description 1
• 241000589634 Xanthomonas Species 0.000 description 1
• 101100351021 Xenopus laevis pax5 gene Proteins 0.000 description 1
• HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
• 108010017070 Zinc Finger Nucleases Proteins 0.000 description 1
• DGEZNRSVGBDHLK-UHFFFAOYSA-N [1,10]phenanthroline Chemical compound C1=CN=C2C3=NC=CC=C3C=CC2=C1 DGEZNRSVGBDHLK-UHFFFAOYSA-N 0.000 description 1
• ILZCVFJUTWHERD-AYQXTPAHSA-N [[(2r,3r,4s,5r)-5-(6-amino-2-chloropurin-9-yl)-4-fluoro-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl] phosphono hydrogen phosphate Chemical compound C1=NC=2C(N)=NC(Cl)=NC=2N1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)[C@@H]1F ILZCVFJUTWHERD-AYQXTPAHSA-N 0.000 description 1
• 230000002378 acidificating effect Effects 0.000 description 1
• 230000033289 adaptive immune response Effects 0.000 description 1
• 210000005006 adaptive immune system Anatomy 0.000 description 1
• 230000002730 additional effect Effects 0.000 description 1
• 229960000643 adenine Drugs 0.000 description 1
• 210000004504 adult stem cell Anatomy 0.000 description 1
• 239000000443 aerosol Substances 0.000 description 1
• 239000003905 agrochemical Substances 0.000 description 1
• 235000004279 alanine Nutrition 0.000 description 1
• 125000000217 alkyl group Chemical group 0.000 description 1
• 229940100198 alkylating agent Drugs 0.000 description 1
• 239000002168 alkylating agent Substances 0.000 description 1
• 208000026935 allergic disease Diseases 0.000 description 1
• 238000011316 allogeneic transplantation Methods 0.000 description 1
• 150000001412 amines Chemical class 0.000 description 1
• 210000004102 animal cell Anatomy 0.000 description 1
• 239000003242 anti bacterial agent Substances 0.000 description 1
• 230000006023 anti-tumor response Effects 0.000 description 1
• 230000000840 anti-viral effect Effects 0.000 description 1
• 229940088710 antibiotic agent Drugs 0.000 description 1
• 229940125644 antibody drug Drugs 0.000 description 1
• 238000011394 anticancer treatment Methods 0.000 description 1
• 230000001640 apoptogenic effect Effects 0.000 description 1
• ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
• 125000003118 aryl group Chemical group 0.000 description 1
• 235000009582 asparagine Nutrition 0.000 description 1
• 229960001230 asparagine Drugs 0.000 description 1
• 235000003704 aspartic acid Nutrition 0.000 description 1
• 239000012298 atmosphere Substances 0.000 description 1
• 230000003190 augmentative effect Effects 0.000 description 1
• 229960002170 azathioprine Drugs 0.000 description 1
• LMEKQMALGUDUQG-UHFFFAOYSA-N azathioprine Chemical compound CN1C=NC([N+]([O-])=O)=C1SC1=NC=NC2=C1NC=N2 LMEKQMALGUDUQG-UHFFFAOYSA-N 0.000 description 1
• 125000000852 azido group Chemical group *N=[N+]=[N-] 0.000 description 1
• 208000022362 bacterial infectious disease Diseases 0.000 description 1
• OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
• 239000002551 biofuel Substances 0.000 description 1
• 238000001574 biopsy Methods 0.000 description 1
• 230000015572 biosynthetic process Effects 0.000 description 1
• 230000000903 blocking effect Effects 0.000 description 1
• 210000004556 brain Anatomy 0.000 description 1
• MJQUEDHRCUIRLF-YCVQJEHTSA-N bryostatins Chemical compound C([C@@H]1CC(/[C@@H]([C@@](C(C)(C)/C=C/2)(O)O1)OC(=O)/C=C/C=C/CCC)=C\C(=O)OC)C([C@@H](C)O)OC(=O)C[C@H](O)C[C@@H](O1)C[C@H](OC(C)=O)C(C)(C)[C@]1(O)C[C@@H]1C\C(=C\C(=O)OC)C[C@H]\2O1 MJQUEDHRCUIRLF-YCVQJEHTSA-N 0.000 description 1
• 239000011575 calcium Substances 0.000 description 1
• 229910052791 calcium Inorganic materials 0.000 description 1
• 239000003710 calcium ionophore Substances 0.000 description 1
• HIYAVKIYRIFSCZ-UHFFFAOYSA-N calcium ionophore A23187 Natural products N=1C2=C(C(O)=O)C(NC)=CC=C2OC=1CC(C(CC1)C)OC1(C(CC1C)C)OC1C(C)C(=O)C1=CC=CN1 HIYAVKIYRIFSCZ-UHFFFAOYSA-N 0.000 description 1
• 229960000846 camphor Drugs 0.000 description 1
• 229930008380 camphor Natural products 0.000 description 1
• 230000036952 cancer formation Effects 0.000 description 1
• 125000002837 carbocyclic group Chemical group 0.000 description 1
• 229960004562 carboplatin Drugs 0.000 description 1
• 190000008236 carboplatin Chemical compound 0.000 description 1
• 231100000504 carcinogenesis Toxicity 0.000 description 1
• 230000030833 cell death Effects 0.000 description 1
• 210000000170 cell membrane Anatomy 0.000 description 1
• 239000006285 cell suspension Substances 0.000 description 1
• 230000008859 change Effects 0.000 description 1
• 238000012512 characterization method Methods 0.000 description 1
• 239000003638 chemical reducing agent Substances 0.000 description 1
• 239000012829 chemotherapy agent Substances 0.000 description 1
• 208000018805 childhood acute lymphoblastic leukemia Diseases 0.000 description 1
• 201000011633 childhood acute lymphocytic leukemia Diseases 0.000 description 1
• 229960000724 cidofovir Drugs 0.000 description 1
• DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 1
• 229960004316 cisplatin Drugs 0.000 description 1
• ZNEWHQLOPFWXOF-UHFFFAOYSA-N coenzyme M Chemical compound OS(=O)(=O)CCS ZNEWHQLOPFWXOF-UHFFFAOYSA-N 0.000 description 1
• 230000002860 competitive effect Effects 0.000 description 1
• 239000002299 complementary DNA Substances 0.000 description 1
• 230000001276 controlling effect Effects 0.000 description 1
• 230000000139 costimulatory effect Effects 0.000 description 1
• 239000012228 culture supernatant Substances 0.000 description 1
• XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
• 235000018417 cysteine Nutrition 0.000 description 1
• 230000016396 cytokine production Effects 0.000 description 1
• 239000000824 cytostatic agent Substances 0.000 description 1
• 231100000433 cytotoxic Toxicity 0.000 description 1
• 230000034994 death Effects 0.000 description 1
• 231100000517 death Toxicity 0.000 description 1
• 230000007123 defense Effects 0.000 description 1
• 230000003112 degranulating effect Effects 0.000 description 1
• 239000000412 dendrimer Substances 0.000 description 1
• 229920000736 dendritic polymer Polymers 0.000 description 1
• 239000005549 deoxyribonucleoside Substances 0.000 description 1
• 230000000779 depleting effect Effects 0.000 description 1
• 238000010586 diagram Methods 0.000 description 1
• 238000006471 dimerization reaction Methods 0.000 description 1
• BFMYDTVEBKDAKJ-UHFFFAOYSA-L disodium;(2',7'-dibromo-3',6'-dioxido-3-oxospiro[2-benzofuran-1,9'-xanthene]-4'-yl)mercury;hydrate Chemical compound O.[Na+].[Na+].O1C(=O)C2=CC=CC=C2C21C1=CC(Br)=C([O-])C([Hg])=C1OC1=C2C=C(Br)C([O-])=C1 BFMYDTVEBKDAKJ-UHFFFAOYSA-L 0.000 description 1
• 230000002222 downregulating effect Effects 0.000 description 1
• 229960004679 doxorubicin Drugs 0.000 description 1
• 238000012377 drug delivery Methods 0.000 description 1
• 241001493065 dsRNA viruses Species 0.000 description 1
• 102100034175 eIF-2-alpha kinase GCN2 Human genes 0.000 description 1
• 210000000959 ear middle Anatomy 0.000 description 1
• 239000002961 echo contrast media Substances 0.000 description 1
• 210000001671 embryonic stem cell Anatomy 0.000 description 1
• 239000000839 emulsion Substances 0.000 description 1
• 238000001976 enzyme digestion Methods 0.000 description 1
• 150000002148 esters Chemical class 0.000 description 1
• 150000002170 ethers Chemical class 0.000 description 1
• CJAONIOAQZUHPN-KKLWWLSJSA-N ethyl 12-[[2-[(2r,3r)-3-[2-[(12-ethoxy-12-oxododecyl)-methylamino]-2-oxoethoxy]butan-2-yl]oxyacetyl]-methylamino]dodecanoate Chemical compound CCOC(=O)CCCCCCCCCCCN(C)C(=O)CO[C@H](C)[C@@H](C)OCC(=O)N(C)CCCCCCCCCCCC(=O)OCC CJAONIOAQZUHPN-KKLWWLSJSA-N 0.000 description 1
• VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 description 1
• 229960005420 etoposide Drugs 0.000 description 1
• 210000003527 eukaryotic cell Anatomy 0.000 description 1
• 102000013165 exonuclease Human genes 0.000 description 1
• 238000013213 extrapolation Methods 0.000 description 1
• 230000001605 fetal effect Effects 0.000 description 1
• 239000012467 final product Substances 0.000 description 1
• 229960000304 folic acid Drugs 0.000 description 1
• 235000019152 folic acid Nutrition 0.000 description 1
• 239000011724 folic acid Substances 0.000 description 1
• 230000037406 food intake Effects 0.000 description 1
• 238000010230 functional analysis Methods 0.000 description 1
• 238000002825 functional assay Methods 0.000 description 1
• 238000012224 gene deletion Methods 0.000 description 1
• 238000010363 gene targeting Methods 0.000 description 1
• 238000007429 general method Methods 0.000 description 1
• 210000004602 germ cell Anatomy 0.000 description 1
• 235000013922 glutamic acid Nutrition 0.000 description 1
• 239000004220 glutamic acid Substances 0.000 description 1
• ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
• 150000002339 glycosphingolipids Chemical class 0.000 description 1
• 239000003102 growth factor Substances 0.000 description 1
• 230000003394 haemopoietic effect Effects 0.000 description 1
• 229910052736 halogen Inorganic materials 0.000 description 1
• 150000002367 halogens Chemical class 0.000 description 1
• 230000036541 health Effects 0.000 description 1
• 210000003958 hematopoietic stem cell Anatomy 0.000 description 1
• 238000011134 hematopoietic stem cell transplantation Methods 0.000 description 1
• 208000006454 hepatitis Diseases 0.000 description 1
• 231100000283 hepatitis Toxicity 0.000 description 1
• 238000002744 homologous recombination Methods 0.000 description 1
• 230000006801 homologous recombination Effects 0.000 description 1
• 239000005556 hormone Substances 0.000 description 1
• 229940088597 hormone Drugs 0.000 description 1
• 238000001794 hormone therapy Methods 0.000 description 1
• 102000047279 human B2M Human genes 0.000 description 1
• 238000013415 human tumor xenograft model Methods 0.000 description 1
• 229910052739 hydrogen Inorganic materials 0.000 description 1
• 230000007062 hydrolysis Effects 0.000 description 1
• 238000006460 hydrolysis reaction Methods 0.000 description 1
• 125000001165 hydrophobic group Chemical group 0.000 description 1
• 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
• 230000009610 hypersensitivity Effects 0.000 description 1
• 201000006866 hypopharynx cancer Diseases 0.000 description 1
• 238000003384 imaging method Methods 0.000 description 1
• 210000001822 immobilized cell Anatomy 0.000 description 1
• 230000002519 immonomodulatory effect Effects 0.000 description 1
• 230000005965 immune activity Effects 0.000 description 1
• 230000005931 immune cell recruitment Effects 0.000 description 1
• 230000037189 immune system physiology Effects 0.000 description 1
• 230000000984 immunochemical effect Effects 0.000 description 1
• 230000005847 immunogenicity Effects 0.000 description 1
• 229960003444 immunosuppressant agent Drugs 0.000 description 1
• 238000002650 immunosuppressive therapy Methods 0.000 description 1
• 238000011065 in-situ storage Methods 0.000 description 1
• 210000004263 induced pluripotent stem cell Anatomy 0.000 description 1
• 210000002602 induced regulatory T cell Anatomy 0.000 description 1
• 230000008595 infiltration Effects 0.000 description 1
• 238000001764 infiltration Methods 0.000 description 1
• 230000000977 initiatory effect Effects 0.000 description 1
• 230000015788 innate immune response Effects 0.000 description 1
• 229940125396 insulin Drugs 0.000 description 1
• 230000003993 interaction Effects 0.000 description 1
• 230000014828 interferon-gamma production Effects 0.000 description 1
• 108010074108 interleukin-21 Proteins 0.000 description 1
• 108010074109 interleukin-22 Proteins 0.000 description 1
• 201000002313 intestinal cancer Diseases 0.000 description 1
• 208000014899 intrahepatic bile duct cancer Diseases 0.000 description 1
• 238000007918 intramuscular administration Methods 0.000 description 1
• 238000010253 intravenous injection Methods 0.000 description 1
• UWKQSNNFCGGAFS-XIFFEERXSA-N irinotecan Chemical compound C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 UWKQSNNFCGGAFS-XIFFEERXSA-N 0.000 description 1
• 229960004768 irinotecan Drugs 0.000 description 1
• 210000004153 islets of langerhan Anatomy 0.000 description 1
• 238000002955 isolation Methods 0.000 description 1
• 210000003734 kidney Anatomy 0.000 description 1
• 150000002596 lactones Chemical class 0.000 description 1
• 239000002523 lectin Substances 0.000 description 1
• 210000000265 leukocyte Anatomy 0.000 description 1
• 239000002502 liposome Substances 0.000 description 1
• 208000003747 lymphoid leukemia Diseases 0.000 description 1
• 210000003563 lymphoid tissue Anatomy 0.000 description 1
• 230000002934 lysing effect Effects 0.000 description 1
• 239000003120 macrolide antibiotic agent Substances 0.000 description 1
• 229920002521 macromolecule Polymers 0.000 description 1
• 238000012423 maintenance Methods 0.000 description 1
• 210000001161 mammalian embryo Anatomy 0.000 description 1
• 230000010534 mechanism of action Effects 0.000 description 1
• 229930182817 methionine Natural products 0.000 description 1
• 230000011987 methylation Effects 0.000 description 1
• 238000007069 methylation reaction Methods 0.000 description 1
• 238000000520 microinjection Methods 0.000 description 1
• 230000002297 mitogenic effect Effects 0.000 description 1
• 238000007479 molecular analysis Methods 0.000 description 1
• 229960005358 monensin Drugs 0.000 description 1
• GAOZTHIDHYLHMS-KEOBGNEYSA-N monensin A Chemical compound C([C@@](O1)(C)[C@H]2CC[C@@](O2)(CC)[C@H]2[C@H](C[C@@H](O2)[C@@H]2[C@H](C[C@@H](C)[C@](O)(CO)O2)C)C)C[C@@]21C[C@H](O)[C@@H](C)[C@@H]([C@@H](C)[C@@H](OC)[C@H](C)C(O)=O)O2 GAOZTHIDHYLHMS-KEOBGNEYSA-N 0.000 description 1
• 238000011395 multi-agent chemotherapy Methods 0.000 description 1
• 238000002703 mutagenesis Methods 0.000 description 1
• 231100000350 mutagenesis Toxicity 0.000 description 1
• 229940014456 mycophenolate Drugs 0.000 description 1
• 229960000951 mycophenolic acid Drugs 0.000 description 1
• 201000000050 myeloid neoplasm Diseases 0.000 description 1
• 239000002105 nanoparticle Substances 0.000 description 1
• 229910052757 nitrogen Inorganic materials 0.000 description 1
• 231100001160 nonlethal Toxicity 0.000 description 1
• 238000007899 nucleic acid hybridization Methods 0.000 description 1
• 239000002777 nucleoside Substances 0.000 description 1
• 150000003833 nucleoside derivatives Chemical class 0.000 description 1
• 238000002515 oligonucleotide synthesis Methods 0.000 description 1
• 238000005457 optimization Methods 0.000 description 1
• 230000008520 organization Effects 0.000 description 1
• 229940046781 other immunosuppressants in atc Drugs 0.000 description 1
• 230000002018 overexpression Effects 0.000 description 1
• 230000036961 partial effect Effects 0.000 description 1
• 239000002245 particle Substances 0.000 description 1
• 229940049954 penicillin Drugs 0.000 description 1
• 210000004976 peripheral blood cell Anatomy 0.000 description 1
• 238000002823 phage display Methods 0.000 description 1
• 230000000144 pharmacologic effect Effects 0.000 description 1
• 230000026731 phosphorylation Effects 0.000 description 1
• 238000006366 phosphorylation reaction Methods 0.000 description 1
• 238000005375 photometry Methods 0.000 description 1
• 238000001126 phototherapy Methods 0.000 description 1
• BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 1
• 201000003437 pleural cancer Diseases 0.000 description 1
• 229920000642 polymer Polymers 0.000 description 1
• 230000004537 potential cytotoxicity Effects 0.000 description 1
• 238000004321 preservation Methods 0.000 description 1
• 230000000861 pro-apoptotic effect Effects 0.000 description 1
• 230000000770 proinflammatory effect Effects 0.000 description 1
• 230000002062 proliferating effect Effects 0.000 description 1
• 230000002035 prolonged effect Effects 0.000 description 1
• 230000000069 prophylactic effect Effects 0.000 description 1
• 150000003180 prostaglandins Chemical class 0.000 description 1
• 201000001514 prostate carcinoma Diseases 0.000 description 1
• 150000003834 purine nucleoside derivatives Chemical class 0.000 description 1
• 239000002719 pyrimidine nucleotide Substances 0.000 description 1
• 230000005855 radiation Effects 0.000 description 1
• 239000002994 raw material Substances 0.000 description 1
• 230000007115 recruitment Effects 0.000 description 1
• 230000000306 recurrent effect Effects 0.000 description 1
• 230000008929 regeneration Effects 0.000 description 1
• 238000011069 regeneration method Methods 0.000 description 1
• 238000009256 replacement therapy Methods 0.000 description 1
• 238000011160 research Methods 0.000 description 1
• 201000008933 retinal cancer Diseases 0.000 description 1
• 230000001177 retroviral effect Effects 0.000 description 1
• 230000002441 reversible effect Effects 0.000 description 1
• 238000012552 review Methods 0.000 description 1
• 229960003452 romidepsin Drugs 0.000 description 1
• OHRURASPPZQGQM-GCCNXGTGSA-N romidepsin Chemical compound O1C(=O)[C@H](C(C)C)NC(=O)C(=C/C)/NC(=O)[C@H]2CSSCC\C=C\[C@@H]1CC(=O)N[C@H](C(C)C)C(=O)N2 OHRURASPPZQGQM-GCCNXGTGSA-N 0.000 description 1
• 238000009094 second-line therapy Methods 0.000 description 1
• 230000008313 sensitization Effects 0.000 description 1
• 238000004904 shortening Methods 0.000 description 1
• 230000009131 signaling function Effects 0.000 description 1
• 230000005783 single-strand break Effects 0.000 description 1
• 238000002741 site-directed mutagenesis Methods 0.000 description 1
• 229940054269 sodium pyruvate Drugs 0.000 description 1
• 239000000243 solution Substances 0.000 description 1
• 238000010561 standard procedure Methods 0.000 description 1
• 229960005322 streptomycin Drugs 0.000 description 1
• 238000007920 subcutaneous administration Methods 0.000 description 1
• 239000000758 substrate Substances 0.000 description 1
• 150000008163 sugars Chemical class 0.000 description 1
• 239000006228 supernatant Substances 0.000 description 1
• 239000004094 surface-active agent Substances 0.000 description 1
• 238000001356 surgical procedure Methods 0.000 description 1
• 208000024891 symptom Diseases 0.000 description 1
• 208000011580 syndromic disease Diseases 0.000 description 1
• 238000003786 synthesis reaction Methods 0.000 description 1
• 238000002626 targeted therapy Methods 0.000 description 1
• 229950010127 teplizumab Drugs 0.000 description 1
• ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 1
• 229940124597 therapeutic agent Drugs 0.000 description 1
• 229940126622 therapeutic monoclonal antibody Drugs 0.000 description 1
• 229940113082 thymine Drugs 0.000 description 1
• 210000001541 thymus gland Anatomy 0.000 description 1
• 238000004448 titration Methods 0.000 description 1
• 210000003014 totipotent stem cell Anatomy 0.000 description 1
• 231100000331 toxic Toxicity 0.000 description 1
• 230000002588 toxic effect Effects 0.000 description 1
• 230000001988 toxicity Effects 0.000 description 1
• 231100000419 toxicity Toxicity 0.000 description 1
• 231100000027 toxicology Toxicity 0.000 description 1
• 238000013518 transcription Methods 0.000 description 1
• 230000035897 transcription Effects 0.000 description 1
• 230000001131 transforming effect Effects 0.000 description 1
• 230000009261 transgenic effect Effects 0.000 description 1
• 238000013519 translation Methods 0.000 description 1
• 102000035160 transmembrane proteins Human genes 0.000 description 1
• 108091005703 transmembrane proteins Proteins 0.000 description 1
• 238000011277 treatment modality Methods 0.000 description 1
• 231100000588 tumorigenic Toxicity 0.000 description 1
• 230000000381 tumorigenic effect Effects 0.000 description 1
• 230000007306 turnover Effects 0.000 description 1
• 230000004222 uncontrolled growth Effects 0.000 description 1
• 241000701447 unidentified baculovirus Species 0.000 description 1
• 241001529453 unidentified herpesvirus Species 0.000 description 1
• 241000712461 unidentified influenza virus Species 0.000 description 1
• 238000011144 upstream manufacturing Methods 0.000 description 1
• 208000007089 vaccinia Diseases 0.000 description 1
• 238000010200 validation analysis Methods 0.000 description 1
• 230000009385 viral infection Effects 0.000 description 1
• 239000011782 vitamin Substances 0.000 description 1
• 235000013343 vitamin Nutrition 0.000 description 1
• 229940088594 vitamin Drugs 0.000 description 1
• 229930003231 vitamin Natural products 0.000 description 1
• 238000012447 xenograft mouse model Methods 0.000 description 1
• 239000011701 zinc Substances 0.000 description 1
• 229910052725 zinc Inorganic materials 0.000 description 1